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1 Introduction 
1 Introduction 
 
Coronary artery disease, stroke and other cerebrovascular diseases, all of which are direct 
consequences of atherosclerosis are the new scourge of humanity. One fourth of all fatalities 
in developed countries are attributable to atherosclerosis-related diseases. Thus, 
cardiovascular events lead the statistics for causes of morbidity and mortality relegating 
cancer to the second (World Health Organization, Fact sheet No 310, November 2008). 
However, increased prevalence of atherosclerosis is not only due to prolonged life time by 
improved health care and education in western society. In fact, high-cholesterol, unhealthy 
nutrition and reduced physical activity widely promote that alarming development. 
One challenge in life sciences is to understand the immunological mechanisms underlying 
atherosclerosis. To improve quality of live and concurrently reduce inconvenient burdens, 
possibilities exploring processes triggering and promoting atherosclerosis are needed. 
Answering questions such as how the immune system is involved and which immune cells 
mainly contribute to atherosclerosis, will probably pave the way for profound understanding 
of pathophysiological processes and thereby delivering concepts for new therapeutic 
approaches. 
 
1.1 Atherosclerosis 
Atherosclerosis is a complex, progressive inflammatory disease of the arterial wall. 
Throughout several stages it is characterized by the accumulation of inflammatory cells, 
lipids and extracellular matrix in the vessel wall that leads to stenosis of arteries.1-3 Plaque 
erosion and rupture trigger intravascular coagulation and thrombus formation, resulting in 
vessel occlusion. Depending on the site of injury this may lead to myocardial infarction or 
stroke, the main causes of death in developed countries.1 
In a first step, endothelial cells are being activated by altered flow, modified low density 
lipoprotein (LDL) as a result of hyperlipidemia, homocystein or bacterial infection thus 
leading to endothelial dysfunction.2 Of note, lipid-lowering by e.g. statins can slow down 
atheroprogression and may reverse it, highlighting the relevance of hypercholesterolemia in 
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the pathophysiology of atherosclerosis.4,5 Once endothelial cells are activated, adhesion and 
infiltration of leukocytes and platelets will be promoted by an increased expression and/or 
release of chemotactic cytokines, chemokines and adhesion molecules. The developing 
inflammatory environment subsequently promotes vessel wall permeability for lipid 
components such as LDL.1 Monocytes that have transmigrated to inflammatory foci in the 
arterial vessel can scavenge oxidized LDL (oxLDL) or other lipids thereby transforming into 
foam cells. These cells then accumulate in the intima thus generating early plaques, also 
known as fatty streaks.6 Not only activated endothelial or smooth muscle cells (SMC) but 
also infiltrated leukocytes furthermore reinforce the inflammation by secretion of a great 
variety of chemokines, cytokines diverse effector molecules and proteases which then 
promote plaque progression, reduction of plaque stability, and ultimately plaque rupture. 
 
1.1.1 Getting there - The leukocyte adhesion cascade 
One of the most important requirements for development of atherosclerosis is the 
continuous recruitment of various leukocyte subsets, especially monocytes. Thus, the 
question of how leukocytes get to sites of inflammation is indispensable. The classical model 
of leukocyte adhesion was a three step cascade. The postulated stages were the selectin-
mediated rolling, followed by chemokine triggered activation and integrin-dependent arrest 
as the final step.7-9 However, during the past years extensive research has implied that 
additional steps occur not only during integrin-mediated leukocyte adhesion but also in 
adhesion stabilization during a post binding phase9 and transendothelial migration.10 
Moreover, diverse studies provided new insights to signaling events underlying integrin 
activation.11,12 As a consequence an expanded version of the original three-step leukocyte 
adhesion cascade including slow rolling, adhesion strengthening, intraluminal crawling, 
paracellular and transcellular migration has established (Figure 1).8 
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Figure 1: The updated leukocyte adhesion cascade. The original three steps of the adhesion cascade are shown in bold: 
selectin-mediated rolling, chemokine-triggered activation and integrin-mediated adhesion. Additional steps such as capture 
(or tethering), slow rolling, adhesion strengthening and spreading, intravascular crawling, paracellular and transcellular 
transmigration have been added. ESAM, endothelial cell-selective adhesion molecule; ICAM1, intercellular adhesion 
molecule 1; JAM, junctional adhesion molecule; LFA1, lymphocyte function-associated antigen 1 (also known as αLβ2-
integrin); MAC1, macrophage antigen 1; MADCAM1, mucosal vascular addressin cell-adhesion molecule 1; PSGL1, P-selectin 
glycoprotein ligand 1; PECAM1, platelet/endothelial-cell adhesion molecule 1; PI3K, phosphoinositide 3-kinase; VCAM1, 
vascular cell-adhesion molecule 1; VLA4, very late antigen 4 (also known as α4β1-integrin) (Adapted from Ley et al.
8) 
Leukocyte adhesion is tightly regulated by selectins, chemokines and cell adhesion molecules 
(CAMs)8,13,14 and thereby all of these molecules are essential in development of 
atherosclerosis. P-selectin for example which is expressed on monocytes, neutrophils and 
lymphocytes,15 is upregulated in human atherosclerotic plaque whereas it is not expressed 
on non-inflamed endothelium.16 Mice deficient of P-selectin displayed lower macrophage 
numbers in the plaque and developed smaller fatty streaks.17 Similar effects on plaque 
development were observed in E-selectin deficient mice.18 Interfering with chemokine-
dependent activation has widely been described to protect from atherosclerosis.13,19,20 CCL5 
for example, as well as other chemokines have been shown to be deposited onto inflamed 
endothelium thereby triggering the arrest of rolling monocytes.21,22 Hence, leukocyte 
integrin affinity can be modulated in a chemokine and G-protein coupled receptor (GPCR)-
dependent manner.11,23,24 Monocytes express both α4 as well as β2-integrins interacting with 
endothelial VCAM-1 and ICAM-1, respectively. Absence of either ICAM-1 or β-integrins or 
both led to reduction of aortic root lesion sizes.25 
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1.1.2 Trigger units – Chemokines and their receptors in atherosclerosis 
Chemokines are a superfamily of small (8-10kDa) chemotactic cytokines that function in 
leukocyte trafficking and activation.26 About 40 different chemokines have so far been 
identified. Those chemokines can interact with about 17 different chemokine receptors 
which are expressed on different subsets of leukocytes. According to the position of the N-
terminal cysteines, chemokines can be classified in four subgroups. The majority belongs to 
the CC group, where the cysteines are adjacent to each other, followed by CXC chemokines 
with the first cysteines separated by a single amino acid residue. Fractalkine is the only 
member of the CX3C group, where the N-terminal cysteines are separated by three amino 
acids. Chemokines belonging to the C group possess only two of the four cysteines present in 
other chemokines.19,27 
The chemokine receptors can be allocated to a superfamily of serpentine proteins that 
signal through coupled heterotrimeric G proteins.28 Until now, more than 600 members of 
the G-protein coupled receptor superfamily have been identified and further classified into 
subgroups.29 Although chemokine receptors can only bind a single class of chemokines they 
are usually highly promiscuous. Thus, a single chemokine can bind to several chemokine 
receptors such that one receptor can possess a variety of ligands with high affinity.30,31 
Additionally, chemokine receptors as well as their ligands are able to form dimers or higher 
order oligomers which further effects affinity and/or signal transduction making the whole 
story even more complex.32 As a consequence, investigating the specific participation of 
single chemokines and chemokine receptors is rather challenging. Up to now, great efforts 
have been made to explore the contribution of chemokine receptors and their ligands in 
atherosclerosis (Table 1) as both are of high interest as future therapeutic targets. 
Regarding the multifaceted chemokine/chemokine receptor interactions, various means of 
interference, such as small molecule receptor antagonists, modification of chemokine 
ligands, or disruption of chemokine pairs, have been considered.33  
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Table 1: Chemokines and their respective receptors in atherosclerosis 
Chemokine Receptor Localization Target 
cell 
Mouse Model Effect on 
atherosclerotic 
lesion size 
CC Chemokine 
CCL2      
(MCP-1) 
CCR2 MM, SMC,EC MM, TC, 
EC 
Ccl2-/-Ldlr-/- 
Ccr2-/-BM>Apoe3-Leiden 
Ccr2-/-Apoe-/- 
 
↓6,34-36 
CCL3       
(MIP-1α) 
CCR1/5 TC MM, TC see CCL5 - 
CCL4       
(MIP-1β) 
CCR5 TC MM, TC, 
SMC 
see CCL5 - 
CCL5 
(RANTES) 
CCR1/3/5 TC MM, TC, 
DC 
Ccr1-/-Apoe-/- 
Ccr1-/-BM>Ldlr-/- 
Ccr5-/-Apoe-/- 
Ccr5-/-BM>Ldlr-/- 
↑37 
↑38 
↓↑39 ↓37 
↓↑40 
CCL7      
(MCP-3) 
CCR1/2 MM, SMC, EC MM see CCL2/5 - 
CCL13     
(MCP-4) 
CCR2/3 MM, EC MM, TC see CCL2 - 
CCL17    
(TARC) 
CCR4/8 MM, DC TC, DC Ccl17egfp/egfpApoe-/- ↓Weber et al., unpublished 
CXC Chemokine 
CXCL1 
(Gro/KC) 
CXCR1/2 MM MM, EC, 
SMC 
Cxcr2-/-BM>Ldlr-/- ↓41 
CXCL4 
(PF4) 
CXCR3B P MM, EC Peptide disrupting CXCL4-
CCL5 heterodimer in Apoe-/- 
↓42 
CXCL8         
(IL-8) 
CXCR1/2 MM MM, EC, 
SMC 
see CXCL1 - 
CXCL9     
(Mig) 
CXCR3 MM, EC, SMC TC Cxcr3-/-Apoe-/- 
CXCR3 antagonist 
Cxcl10-/-Apoe-/- 
 
↓43-46 
CXCL10   
(IP10) 
CXCR3 ?? ?? see CXCL9 - 
CXCL11         
(I-TAC) 
CXCR3 MM, EC MM, TC, 
SMC 
see CXCL9 - 
CXCL12    
(SDF-1α) 
CXCR4 MM, SMC TC, VP Cxcr4-/-BM>Ldlr-/- 
CXCR4 antagonist treatment 
↑47 
CXCL16      
(SR-PSOX) 
CXCR6 MM, DC, SMC TC, NK Cxcl16-/-Ldlr-/- 
Cxcr6-/-Apoe-/- 
↑48 
↓49 
CX3C Chemokine 
CX3CL1 
(Fraktalkine) 
CX3CR1 SMC MM, TC Cx3cl1-/-Apoe-/- 
Cx3cl1-/-Ldlr-/- 
Cx3cr1-/-Apoe-/- 
Cx3cr1-/-BM>Apoe-/- 
Cx3cl1-/-Ccr2-/-Apoe-/- 
Cx3cl1-/-Ccr2-/-Apoe-/- with 
CCL5 peptide inhibition 
 
 
↓50-55 
DC: dendritic cells, EC: endothelial cells, MM: monocytes/macrophages, P: platelets, SMC: smooth muscle cells, 
TC: T-cells, VP: vascular progenitors, ↑: increase, ↓ reduction, ↓↑ no change. (Adapted and modified from 
Weber et al.,19 and Zernecke et al.20) 
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1.2 Myeloid cells in atherosclerosis 
Various leukocyte subsets invade the atherosclerotic lesion, whereof 
monocytes/macrophages and lymphocytes are supposed to primarily dominate 
atherosclerotic development.56,57 However, recent investigations start focusing on so far 
underestimated myeloid cell types such as granulocytes, mast cells or dendritic cells (DC) 
revealing them to be crucial actors in initiation and progression of vascular inflammatory 
processes.15 
CMPCLP
Lymphoid cells
(T-cells, B-cells)
MEP
MDP
Erythrocytes and
Megakaryocytes
Neutrophils
Monocytes
HSCs
GMP
CDP
PDC Pre-cDC
PDC
Pre-
cDC
Dendritic
cells
Bone marrow Blood Tissue
Mφ
M1 Mφ
M2 Mφ
Tip-DC
Inflamed tissue
cDC
PDC
Mφ
Lymphoid tissue
Ly6C-
Ly6C- Ly6C+
Ly6C+
 
Figure 2: Schematic overview of myeloid cell differentiation, mobilization and tissue fate in mice. Common lymphoid 
progenitors (CLP) as well as common myeloid progenitors (CMP) originate from hematopoietic stem cells (HSC) located 
within bone marrow stem cell niches. CMP can further give rise to either megakaryocyte-erythrocyte progenitor (MEP) or 
granulocyte-monocyte progenitors (GMP) which then can either be driven to a granulocytic phenotype e.g. neutrophil or a 
monocyte/macrophage dendritic cell precursor (MDP). MDP can differentiate to monocytes; however it is still under debate 
whether Ly6C-/Gr1- originate from Ly6C+/Gr1+ or an independent progenitor. Additionally, MDP can give rise to dendritic 
cell precursors (CDP) which can also develop from CLP thus, giving birth to either plasmacytoid dendritic (PDC) cells or 
preclassical dendritic cells (Pre-cDC).pPDC, Pre-cDC, Ly6C-/Gr1-, Ly6C+/Gr1+ and neutrophils can be mobilized directly from 
bone marrow to circulation and either under homeostatic conditions end up in lymphoid tissue or in case of inflammation 
be recruited to site of injury to further differentiate into macrophages (Mφ) or Tip-DC. Adapted and modified from 
Geissmann et al.,58 Iwasaki et al.,59 Auffray et al.60 and Akashi et al.61 
 
Thanks to the successful isolation of a common lymphoid progenitor (CLP) giving rise to 
lymphoid but not myeloid cells62 and its counterpart the common myeloid progenitor (CMP) 
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as a source of all myeloid cells61, mature blood cells are traditionally categorized into two 
separate lineages. Lymphoid lineage consists of B, T and natural killer (NK) cells. In contrast, 
myeloid lineage includes different subsets of granulocytes (eosinophils, neutrophils, 
basophils), monocytes, macrophages, megakaryocytes, erythrocytes and mast cells.59 
However, dendritic cells (DC) exhibit a somehow unique developmental program which can 
be activated from either the lymphoid or the myeloid pathways.63,64 Based on 
transplantation studies, a monocyte/macrophage dendritic cell progenitor (MDP) has been 
accepted to be origin of monocytic cells. Sharing phenotypical characteristics with 
granulocytic myeloid progenitors (GMP)61 the MDP gives rise to monocytes, several 
macrophage subsets and cDCs but lacks granulocytic potential (Figure 2).65-67 
As this study primarily focuses on monocytes and neutrophils and especially their presumed 
interaction in atherosclerosis the following paragraphs are supposed to give an overview of 
current state of knowledge in development, homeostasis and fate in inflammation for those 
two myeloid subsets. 
 
1.2.1 Monocytes 
Monocytes as part of innate immune system are phagocytic cells. Yet in Drosophila 
melanogaster they play an important role in development and homeostasis via the removal 
of apoptotic cells and scavenging toxic compounds.68,69 Representing 10% of whole 
leukocytes in human and around 4% in mouse, monocytes are considered to be accessory 
cells linking inflammation and the innate defense against microorganisms to adaptive 
immune responses.60 A widely assumed function of monocytes is to represent a systemic 
reservoir of myeloid precursors for the renewal of tissue macrophages as well as antigen-
presenting cells such as DCs.65,70-72 Monocyte development is primarily dependent on colony 
stimulating factor 1 (CSF-1) which is also known as macrophage colony stimulating factor (M-
CSF). Notably, in mice deficient in CSF-1 receptor (CD115) or M-CSF, the number of blood 
monocytes is dramatically reduced.73-75 On transcriptional level, development and 
differentiation of common myeloid progenitors (CMP), the Ets-family transcription factor 
PU.1 plays an important role. PU.1 can induce myeloid commitment in immature 
multipotent progenitor cells76 and is indispensible for the generation of CMP during early 
myelopoiesis.77,78 Research on the human and mouse CSF-1R/c-fms proximal promotor has 
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revealed that it is trans-activated by PU.1.79 Consistent with that, PU.1-deficient myeloid 
progenitors do not express CSF-1R.80 
Table 2: Phenotypical differences between monocyte subsets in human and mouse 
Subset Human  Mouse  
 Classical Non-classical Inflammatory Resident 
Adhesion molecules 
CD62L ++ - ++ - 
PSGL-1 ++ + ++ + 
CD44 nd nd + + 
CD11a nd nd + ++ 
CD11b ++ ++ ++ ++ 
CD49b nd nd + - 
Chemokine receptors 
CCR1 + - ++ + 
CCR2 ++ - ++ + 
CCR5 + + + + 
CX3CR1 + ++ + ++ 
Others 
F4/80 nd nd + + 
Gr1 nd nd + - 
CD115 ++ ++ ++ ++ 
MHCII + ++ - - 
CD68 ++ ++ + + 
nd not determined, - not expressed, + low expression, ++ high expression (adapted from Soehnlein et al.15) 
 
The mechanisms how monocytes can enter sites of inflammation and the importance of 
selectins, chemokines and CAMs have already been discussed in a previous section (1.1.1). 
However, the concepts of monocyte influx into atherosclerotic lesions is much more 
complex than it has been taken into account in early studies. Two principal monocyte 
subsets exist in both human and mouse.72 In humans, monocytes can be differentiated by 
expression of CD14 and CD16.81,82 Classical monocytes are defined as CD14+CD16- whereas 
non-classical monocytes are CD14lowCD16+. In mice, monocyte subsets can be classified by 
expression of lymphocyte antigen 6C (Ly6C) which is part of the granulocyte differentiation 
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antigen Gr-1 and specific for monocytes whereas the other part, Ly6G is only present on 
granulocytes. Monocytes being Ly6C+/Gr1+ are CX3CR1lowCCR2+ and thought to correspond 
to human classical monocytes. In contrast, murine Ly6C-/Gr1- monocytes CX3CR1highCCR2- 
are phenotypic equivalents of human non-classical monocytes.15 However, the relative 
distribution of these subsets among total monocyte counts differs between human and 
mouse (90:10 vs. 50:50). Nevertheless they widely exhibit similar expression patterns for a 
variety of adhesion molecules, chemokine receptors and other markers indicating 
comparable functional characteristics in both species (Table 2). Murine Gr1+ monocytes are 
selectively recruited to inflamed tissue and lymph nodes in vivo, produce high levels of TNFα 
and IL-1 during infection or tissue damage and were therefore termed inflammatory 
monocytes. 60,72,83 Gr1+ monocyte homeostasis seems to be tightly regulated by the MCP-
1/CCR2 axis. Thus, under inflammatory conditions, murine Gr1+ monocytes are massively 
mobilized from bone marrow in a CCL2 (MCP-1), CCL7 (MCP-3) – CCR2 dependent fashion 
(Figure 3).70,84 Interestingly, in a more recent study the spleen has been shown to be a 
reservoir for inflammatory monocytes. In accordance with this finding, splenectomized mice 
failed to develop a monocytosis under acute inflammatory conditions.85 Once recruited to 
sites of inflammation, Gr1+ monocytes are supposed to preferentially differentiate to M1 
macrophages or TNFα producing Tip-DCs.60 In contrast, extravasated Gr1- monocytes initiate 
a typical macrophage differentiation program by expression and upregulation of markers 
typical for alternatively activated, also termed M2-like macrophages (Figure 2).86,87 Although 
Gr1- monocytes are supposed to originate from Gr1+ monocytes that have already 
circulated,88,89 the underlying homeostatic mechanisms remain elusive. A specific progenitor 
for that monocyte subset seems not to be unlikely though it could not be detected so far. 
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Figure 3: Model of regulation of monocyte homeostasis. Monocyte homeostasis is primarily regulated by CCL2 (MCP-1), 
CCL7 (MCP-3) and CCR2. Under inflammatory conditions with increased amounts of CCL2 and CCL7, Gr1+ monocytes are 
massively mobilized from either bone marrow or spleen.70,84,85 
 
Monocytes and monocyte-derived macrophages which can ultimately form foam cells after 
uptake of lipid components are usually seen as the most abundant myeloid cell population 
within the atherosclerotic lesion. About 25 years ago, monocytes were proven to be present 
in both human plaques and lesions obtained from animal models.90,91 Direct evidence for 
monocytes´ relevance in atherogenesis could be demonstrated in a study where depletion 
of monocytes reduced the plaque formation in rabbits.92 However, a more recent study 
concentrated on the question whether depletion of monocytes and macrophages during 
early or later stages differentially affects atherogenesis.93 Although the animal model used 
has to be rated as critical, depletion during early stages led to decreased plaque size 
accompanied by reduced macrophage numbers, collagen content and necrotic core within 
the lesion whereas depletion during later stages did not have any of those effects suggesting 
the importance of monocytes during early stages of atherogenesis.93 Interestingly, with 
respect to the need for CSF-1 in monocyte development, mice deficient for both CSF-1 and 
Apolipoprotein E (ApoE) display reduced lesion sizes preferentially during early stages of 
atherosclerosis but increased serum cholesterol levels highlighting both monocytes´ 
significance in scavenging lipid components and importance during early stages.94 Taken 
together, the prominent role of monocytes in general is without doubt. However, the 
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specific contribution of monocyte subsets in atherosclerosis remains elusive. The 
involvement of selectins and CAMs for example has traditionally been investigated for whole 
monocyte population whereas recent data indicate distinct engagement patterns of these 
receptors for monocyte subsets.15 For instance, PSGL-1 has been demonstrated to be 
expressed at higher levels on inflammatory monocytes and that way is crucially involved in 
the interaction of Gr1+ monocytes with the atherosclerotic endothelium.95 Furthermore 
inflammatory monocytes express higher amounts of CD62L and CD49b as compared to their 
resident counterparts.15 Under high fat diet (HFD) increased numbers of inflammatory 
monocytes have been reported whereas the number of resident monocytes was not 
altered.96 The spatial and temporal course of Gr1+ monocytosis development clearly showed 
progressive expansion of those cells in bone marrow, blood and spleen under HFD. Reasons 
for that were supposed to be increased survival, continued proliferation and impaired Gr1+ 
to Gr1- conversion.96 Those effects may be directly related to increased serum cholesterol 
levels as HFD-induced monocytosis neither could be observed in Apoe+/+ mice nor in Apoe-/- 
fed normal chow. Of note, administration of statins attenuated monocytosis, highlighting the 
importance of serum cholesterol. However, the mechanistic link between serum cholesterol 
and HFD induced Gr1+ monocytosis remains unclear. The chemokine receptor CX3CR1 may 
also be of importance as it confers a survival signal which prevents cell death of monocytes 
and foam cells.50 Besides a possible role of chemokine receptors in cell endurance, 
inflammatory monocytes were depicted to emigrate into atherosclerotic lesions by utilizing 
CX3CR1, CCR2 and CCR5.89 In contrast, resident monocytes not only seem to employ 
mechanisms different from those of inflammatory monocytes for extravasation, their 
possible function at sites of atherosclerosis further differs. Recently it has been shown that 
Gr1- monocytes patrol healthy tissues through CX3CR1-dependent crawling on non-activated 
endothelium, which allows their rapid tissue infiltration at sites of infection or injury.97 While 
this mechanism could be observed within microcirculation, it has not been shown in large 
arteries. There, they rather seem to employ CCR5 for extravasation.89 
Although monocytes have been extensively investigated, especially in context of 
atherosclerosis the importance of either monocyte subset in onset and progression remains 
elusive. The mechanisms underlying recruitment or migration of either subset to sites of 
atherosclerosis and the involvement of chemokines and their receptors are so far poorly 
understood and require further dissection. 
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1.2.2 Neutrophils 
Neutrophils, representing around 70% of whole human white blood cells, are key players in 
innate immunity. As professional phagocytic cells they are able to phagocyte and destroy 
infectious agents thereby acting as first line in host defense.98 The bone marrow is the sole 
place for granulopoiesis and under inflammatory conditions neutrophils are massively 
mobilized to the circulation.99 Under steady state conditions only a small fraction of the 
bone marrow neutrophil pool is released into the blood and mature neutrophils are rapidly 
cleared with a half-life of 6-8h.98 Both, monocytes and granulocytes stem from one common 
granulocyte-monocytes-precursor (GMP) (Figure 2). While M-CSF drives precursor cells 
towards a monocyte phenotype (1.2.1), granulocyte development is primarily regulated by 
granulocyte colony stimulating factor (G-CSF).100 The indispensible role of G-CSF in 
granulopoiesis is supported by the fact that mice deficient of G-CSF display a severe, but not 
absolute neutropenia.101,102 Worth mentioning is the role of other hematopoietic cytokines 
such as IL-3, IL-6 and GM-CSF, as they all stimulate granulopoiesis in vivo.103-105 However, 
mice deficient of either IL-3, IL-6 or GM-CSF display no defects in basal granulopoiesis 
suggesting a replaceable role of those chemokines in hematopoiesis.106-108 PU.1 and CCAAT 
enhancer binding protein (C/EBP) not only play an important role in monocyte development. 
Also in granulopoiesis a variety of transcription factors seem to be essential109 as for instance 
PU.1 knockout cells fail to express G-CSF receptor and are functionally incompetent.110  
As a consequence of the comparably short half-life of neutrophils in the circulation, 
phenotypical changes of these cells that could influence their recruitment behavior following 
mobilization seem to be unlikely. In contrast, accumulation and activation of excessive 
numbers of neutrophils can have a deleterious effect, contributing to tissue damage in 
inflammatory disorders111 implying the indispensible role of neutrophil homeostasis-
regulating factors in onset of inflammation. Thus, to gain a detailed view on either acute or 
chronic inflammation profound understanding of neutrophil homeostasis is required which 
has been described to be tightly regulated by the chemokine receptors CXCR2 and CXCR4.112 
Freshly generated neutrophils are stored within bone marrow and display high expression 
levels of CXCR2. Thus, employing this receptor, neutrophils can efficiently be mobilized by 
specific ligands such as CXCL1 (KC in mouse/Gro-α in human) or IL-8 (CXCL8). However, as 
the CXCR4 expression level on emerging neutrophils is comparably low it serves as a 
retention factor via CXCL12 (SDF1α) that is constitutively expressed in the bone marrow. 
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After release from that site of granulopoiesis, neutrophils undergo senescence in which 
CXCR4 expression increases whereas CXCR2 expression conversely decreases. Thereby, 
senescent CXCR4high neutrophils either undergo apoptosis or return to bone marrow112 
where they are cleared by macrophages.111 An overview of neutrophil homeostasis 
differentially regulated by CXCR2 and CXCR4 is given in Figure 4. 
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Figure 4: Model of neutrophil release and return to the bone marrow. Freshly generated neutrophils in bone marrow are 
CXCR2high/CXCR4low. After mobilization from bone marrow via CXCR2 and its specific ligands, circulating neutrophils undergo 
senescence and their phenotype changes to CXCR2low/CXCR4high. Thereby, senescent neutrophils either return to bone 
marrow employing CXCR4 and SDF1α axis or undergo apoptosis. (adapted from Martin et al.112) 
 
Beside the intriguing model of neutrophil homeostasis based upon the reverse expression of 
the two chemokine receptors CXCR2 and CXCR4 a recent study describes an auto-regulatory 
machinery, linking neutrophil clearance in tissue with neutrophil production and release 
from bone marrow.113 Worth mentioning is that through as yet unknown mechanisms, G-CSF 
potently inhibits osteoblast activity leading to decreased SDF1α expression.114 (Figure 5) 
Additionally another study could demonstrate that the magnitude of neutrophil mobilization 
by G-CSF strongly correlates with the decrease in SDF1α protein expression in the bone 
marrow.115 (Figure 5) Phagocytosis of apoptotic neutrophils by tissue macrophages and DCs 
ultimately leads to down-regulated expression of IL-23 in a NF-κB dependent fashion.115,116 
IL-23 is a potent inducer of IL-17, member of a cytokine family defining the TH17-CD4 
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subpopulation117 and thereby fuels G-CSF secretion.118 Those studies suggest a model where 
granulopoiesis is driven by a cytokine cascade starting with macrophage and dendritic cell IL-
23 secretion. The resulting release of T-cell IL-17 increases G-CSF levels thereby promoting 
granulopoiesis and mobilization.119 (Figure 5) That machinery can be altered by phagocytosis 
of apoptotic neutrophils by tissue macrophages or DCs leading to decreased IL-23 release, 
ultimately exerting a negative feed-back loop to the bone marrow. 
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Figure 5: Regulation of neutrophil homeostasis by a feedback loop involving tissue associated neutrophil clearance. 
SDF1α is constitutively expressed by bone marrow osteoblasts thus retaining neutrophils via CXCR4. (upper left) Protein 
expression of SDF1α is negatively regulated by G-CSF leading to release of neutrophils to circulation. (upper right) IL-23 is 
released by tissue macrophages leading to secretion of IL-17 and G-CSF expression. After phagocytosis of apoptotic 
neutrophils IL-23 release by macrophages is decreased thereby disrupting the IL-23/IL-17/G-CSF-dependent granulopoiesis 
and mobilization. (adapted from Christopher et al.99) 
 
In line with these studies, transgenic overexpression of IL-23-specific subunit p19 in mice 
induced neutrophilia120 whereas deficiency or blockade with an antibody decreased 
neutrophil counts in normal and neutrophilic mice.121 Furthermore, mice deficient of 
adhesion molecules display severe neutrophilia accompanied by elevated IL-17 levels.122 
Blockade of IL-17 could reverse that effect.122 Accordingly, mice deficient in the IL-17 
receptor (Il17ra-/-) show decreased neutrophil counts.123 
 15 
 
1 Introduction 
In contrast to the role of lymphocytes and monocytes/macrophages, involvement of 
neutrophils in atherosclerosis is so far underappreciated. That is mainly due to the fact, that 
neutrophils cannot be detected in high numbers in atherosclerotic lesions. Although, already 
in 1982 Trillo et al showed the presence of polymorphnuclear leukocytes (PMN) in early 
atherosclerotic lesions in monkeys,124 work on neutrophils in atherosclerosis remained 
largely descriptive. Continuative studies could proof a positive correlation between 
neutrophil count and incidence of myocardial infarction.125,126 The functional importance of 
neutrophils could first be described in a recent study. By disrupting the CXCR4/CXCL12 axis 
with a small antagonist, peripheral neutrophil counts increased which was than associated 
with aggravated lesion formation.47 In contrast, depletion of neutrophils significantly 
reduced the plaque size. However, although the importance of neutrophil homeostatic 
regulation could be demonstrated, neither direct evidence nor mechanistic insights have 
been provided by this study. One of the most relevant questions remaining is why 
neutrophils can be detected only in poor numbers within atherosclerotic lesions. Whereas 
inefficient recruitment seems to be unlikely, the relative short half live of neutrophils once 
emigrated could be a possible explanation.15 As the involvement of neutrophils in 
atherogenesis still remains elusive, mechanisms underlying neutrophil recruitment to and 
their importance at sites of atherosclerosis are hypothetical. Of note, neutrophils in murine 
atherosclerosis were shown to accumulate in lesions near the fibrous cap47 and the number 
of apoptotic cells increases in subluminal regions, which might correspond to sites of 
neutrophil accumulation.15 Traditionally the neutrophil is seen to be first line of defense 
during infection by phagocyting and digesting bacteria, producing reactive oxygen species 
and initiating immune responses.127 Much of this ability is mediated by the release of 
preformed granule proteins, which act to alarm neighboring cells.128 Most important 
members of the set of neutrophil-derived alarmins are LL37129 (also known as CRAMP in 
mouse), α-defensins (human neutrophil peptides, HNPs),130 azurocidin (HBP, CAP37),131 as 
well as seprocidins (elastase, cathepsin G, proteinase-3).132 Interestingly, all of these proteins 
have been identified in the atherosclerotic lesion and much of them are found at the luminal 
site of the endothelium133 suggesting their deposition by neutrophils. In this location, these 
proteins may activate monocytes and induce their adhesion.134 The outcome of this would 
be a model of neutrophil recruitment to sites of inflamed endothelium, deposition of granule 
proteins thereby promoting monocyte influx and lesion formation. An additional scenario is 
 16 
 
1 Introduction 
their involvement in plaque stability. Neutrophils are rich in matrixmetalloproteinases 
(MMP)-9, cathepsin G, elastase, and proteinase-3. Through their proteolytic activity, they 
may contribute to weakening of the fibrous cap and ultimately promote plaque rupture.15  
 
1.2.3 Other myeloid cell subsets 
Beside monocyte/macrophages and neutrophils many more myeloid cells are involved in the 
complex pathophysiology of atherosclerosis they will not be discussed in detail here. The 
following paragraph gives a brief overview of myeloid cell subsets and their possible 
importance in atherogenesis. 
Although data from clinical studies indicate that there is no correlation between eosinophil 
or basophil count and degree of atherosclerosis,135 eosinophil and basophil attractants such 
as CCL1115 or MCP-1136 are abundantly expressed in lesions. The role of those cells is further 
supported by the finding of increased numbers of basophils in the aortas of rabbits fed a 
high fat diet.137 Mast cells, intimately involved in wound healing and defense against 
pathogens contain a variety of different granule proteins and have also been identified in 
coronary and carotid-artery plaques at sites of plaque erosion, rupture, or hemorrhage.138 
Local application of mast cell activators was shown to induce intraplaque hemorrhage, 
apoptosis of macrophages, vascular permeability, and monocyte recruitment to mouse 
plaques.139 Further support for their relevance stems from a study with mice lacking mast 
cells. Those animals displayed decreased lesion sizes, lipid deposition, T cell and macrophage 
numbers, cell proliferation, and apoptosis, but increased collagen content and fibrous cap 
development.140 A relevance of DCs in atherogenesis is likely as the numbers of those cells 
were found to be increased in advanced human plaques.141 Involvement of DCs is further 
fueled by the finding that their accumulation in lesions is associated with plaque growth and 
inflammation.142 Although, facing the problem that DCs are a heterogeneous group of 
antigen presenting cells consisting of conventional DC (cDC), plasmacytoid DC (pDC), as well 
as inflammatory DC all of which may be involved in antigen capture, processing and 
stimulation of T cells within peripheral tissue as well as atherosclerotic lesions.143 Oxidized 
low density lipoprotein (oxLDL) may represent such an antigen thereby triggering IFNγ 
production by T cells. That assumption is further supported by studies showing that oxLDL 
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enhances expression of costimulatory molecules by DC with subsequent T cell 
proliferation.144,145 
 
1.3 Aim of the study 
Atherosclerosis with its multifaceted involvement of probably any immune cell, has been 
intensively investigated in the past. Nonetheless we are far from understanding its 
underlying mechanisms and the specific role of immune cell subsets involved. Neutrophils 
for example have been shown to somehow trigger atherosclerosis. They could be detected 
in atherosclerotic lesions of monkeys,124 their count has been proven to correlate with 
cardiovascular events125,126 and finally, neutrophilia could be demonstrated to aggravate 
lesion formation in mouse.47 However, direct evidence for neutrophil participation in lesion 
formation and development of atherosclerosis is so far not given. Thus, the first aim of this 
study was to highlight the role of neutrophils in atherosclerosis. Questions to be answered 
especially addressed neutrophil homeostasis and how it is altered under hyperlipidemic 
conditions, localization of those cells in atherosclerotic lesions and their importance in early 
and later stages of atherogenesis. Of special interest was which chemokine receptors 
triggered arterial as well as venous recruitment of neutrophils. The second part questioned 
the specific involvement of the two distinct monocyte subsets. Although a magnitude of 
studies have been published, supporting the role of monocytes in atherosclerosis, surveys 
dissecting the participation of both monocyte subsets are required. Likewise the significance 
of chemokine receptors has been observed more one-dimensional. Hitherto, studies just 
aimed at lesion sizes and monocyte/macrophage content in general, regardless of changes in 
immune cell homeostasis. Beside the aim of clarifying mechanisms underlying the already 
described monocytosis under high fat diet (HFD) in mice,96 this study especially 
dichotomized the role of chemokine receptors in monocyte homeostasis and arterial 
recruitment. In summary, this study aimed at the alliance between neutrophils and 
monocytes in onset and progression of atherosclerosis trying to answer the question 
whether they are accomplices or not. 
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2 Material and Methods 
2.1 Material 
2.1.1 General equipment and consumables 
 
2.1.1.1 General equipment 
autoclave Systec VX-150 (Systec, Wettenberg, Germany); balances (Sartorius, Göttingen, 
Germany); CCD camera Hamamatsu 9100-02 EMCCD (Hamamatsu, Hamamatsu, Japan); 
centrifuges Eppendorf 5417C (Eppendorf, Hamburg, Germany), Heraeus Labofuge 400 and 
Heraeus Multifuge 3 S-R (Heraeus, Hanau, Germany); flow cytometers FACSCantoII, FACSAria 
(BD Biosciences, San Jose, CA, USA); fluorescence plate reader Infinite M200 (Tecan, 
Crailsheim, Germany); laminar flow hood Herasafe (Heraeus, Hanau, Germany); microscopes 
Olympus IX71 and BX51 (Olympus Optical, Hamburg,Germany), Leica DMLB (Leica, Wetzlar, 
Germany); multiphoton system LaVision Biotec Trimscope (LaVision Biotec GmbH, 
Bielefeld,Germany); PCR thermocyclers MyCycler (Bio-Rad, Hercules, CA), DNA Engine 
Opticon (MJResearch, Hercules, CA, USA); pH-meter Lab850 (Schott, Mainz, Germany); 
spectrometer NanoDrop (Peqlab, Erlangen, Germany); 
2.1.1.2 Consumables 
96well plates flat, round bottom (Nunc, Roskilde, Denmark); cannulas 23G, 27G (BD, Franklin 
Lakes, USA); cell strainer (Miltenyi, Bergisch-Gladbach, Germany); disposable scalpel 
(Feather Safety Razor Co., Osaka, Japan); FACS-tubes (BD, FranklinLakes, USA); microscope 
slides (Thermo Scientific, Braunschweig, Germany); microtubes EDTA, with clot activator for 
sera (Sarstedt, Nümbrecht, Germany); glassware (Schott, Mainz, Germany); reaction cups 
1.5ml, 2.0ml (Sarstedt, Nümbrecht, Germany); reaction tubes 15ml, 50ml (Greiner Bio-one, 
Frickenhausen, Germany); serological pipettes 5ml, 10ml, 25ml (Corning, New York, USA); 
sterile filter-tips (Starlab, Ahrensburg, Germany); syringes 2ml, 5ml, 10ml, 20ml (Terumo, 
Leuven, Belgium), 1ml (Braun, Melsungen, Germany); 
2.1.1.3 Kits 
DNA digestion DNase Set (Quiagen, Hilden, Germany); ELISA Quantikine Immunoassay or 
DuoSet for different Cytokines (both R&D Systems, Minneapolis, USA), Instant ELISA 
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(BenderMedSystems, Vienna, Austria); PCR-Array RT2 Profiler PCR Array System for mouse 
chemokines & receptors (SABiosciences, Frederick, USA); Reverse Transcription M-MLV 
Reverse Transcriptase (Promega, Madison, USA); Real-time PCR Maxima SYBR Green qPCR 
Master Mix (Fermentas, St. Leon-Rot, Germany); RNA isolation RNeasy Mini/Micro Kit 
(Quiagen, Hilden, Germany); TUNEL In Situ Cell Death Detection Kit, TMR red (Roche, Basel, 
Switzerland) 
 
2.1.2 Buffers, chemicals, media, solutions 
Unless stated otherwise, all chemicals were obtained from Merck, Fluka or Sigma-Aldrich in 
analytical grade quality. All solutions were prepared with either Aqua ad injectabilia (Braun, 
Melsungen, Germany) or Millipore water (Milli-Q Plus ultrapure purification, Millipore, 
Billerica, USA). Buffers used are summarized in Table 4. 
 
2.1.3 Peptides, oligonucleotides, antagonists and antibodies 
Peptides, oligonucleotides, antagonists and antibodies used for different experimental 
setups are listed below in Table 3, Table 5 - Table 7. Antagonists were all obtained from 
Tocris bioscience (Bristol, United Kingdom). If not stated otherwise, all antibodies used 
(Table 6) were reactive to mouse. 
Table 3: Peptides 
Peptide Manufacturer 
rmCXCL1 (KC) Peprotech, Hamburg, Germany 
rmTNFα Peprotech, Hamburg, Germany 
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Table 4: Buffers chemicals, media and solutions 
Buffer/Solution/Medium Composition 
FACS staining buffer 2% mouse serum; 2% rabbit serum (both Sigma-Aldrich, St. 
Louis, USA); 2% human serum (Innovative Research, Novi, USA); 
2% bovine serum albumin (BSA) (Serva, Heidelberg, Germany); 
dissolved in PBS 
Hank´s complete HBSS (Invitrogen,Carlsbad, USA), 0.3mM diNaEDTA, 0.1% BSA  
Lysis buffer 150mM NH4Cl; 10mM KHCO3; 0.1mM diNaEDTA, pH 7.4 
Phosphate buffered 
saline (PBS) 
w/o Ca2+ and Mg2+, steril (PAA, Pasching, Austria), pH 7.4 
RPMI Medium RPMI1640 (PAA, Pasching, Austria); 10% fetal calf serum (FCS) 
(PAA, Pasching, Austria) 
Paraformaldehyd 4% Paraformaldehyde, 5% Sucrose, 0.02M EDTA, pH 7.4 
Sirius Red solution 0.1% Sirius Red in picric acid 
0,02M K+ buffer 0.02M KH2PO4, 0.02M K2HPO4, pH 7.4 
0,05M K+ buffer 0.05M KH2PO4, 0.05M K2HPO4, pH 6 
 
Table 5: Oligonucleotides 
Gene Name Abbreviation Forward Primer 5’-3’ Reverse Primer 
Chemokine (C-C 
motif) receptor 1 
Ccr1 AGGGCCCGAACTGTTACTTT TTCCACTGCTTCAGGCTCTT 
Chemokine (C-C 
motif) receptor 2 
Ccr2 ATTCTCCACACCCTGTTTCG GATTCCTGGAAGGTGGTCAA 
Chemokine (C-C 
motif) receptor 5 
Ccr5 ATTCTCCACACCCTGTTTCG GAATTCCTGGAAGGTGGTCA 
Chemokine (C-X-C 
motif) receptor 2 
Cxcr2 GCCTTGAGTCACAGAGAGTTG CAAGGCTCAGCAGAGTCAC 
Chemokine (C-X-C 
motif) receptor 4 
Cxcr4 GGCTGTAGAGCGAGTGTTG CAGAAGGGGAGTGTGATGAC 
Glycerinaldehyd-3-
phosphat-
Dehydrogenase 
Gapdh CCATCACCATCTTCCAGGAG GTGGTTCACACCCATCACAA 
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Table 6: Antibodies  
Antibody Specificity Conjugate Application Manufacturer 
anti CCL2 Chemokine (C-C motif) ligand 2 purified IVM eBioscience 
anti CCL3 Chemokine (C-C motif) ligand 3 purified IVM eBioscience 
anti CCL5 Chemokine (C-C motif) ligand 5 purified IVM eBioscience 
anti CCR1 Chemokine (C-C motif) receptor 1 purified FC Imgenex 
anti CCR5 Chemokine (C-C motif) receptor 5 biotinylated FC BD Biosciences 
anti CD115 Monocytes, Macrophages PE FC eBiosciences 
anti CD115 Monocytes, Macrophages biotinylated FC eBiosciences 
anti CD11b Neutrophils, Monocytes, Macro-
phages 
PerCp, PE-
Cy7 
FC BD Biosciences 
anti CD11c Dendritic cells PE-Cy7 FC eBiosciences 
anti CD19 B-cells PerCP FC BD Biosciences 
anti CD3 T-cells FITC FC BD Biosciences 
anti CD45 All Leukocytes APC-Cy7 FC BD Biosciences 
anti CKR2 Chemokine (C-C motif) receptor 2 purified FC Epitomics 
anti CX3CR1 Chemokine (C-X3-C) receptor 1 purified FC R&D Systems 
anti CXCL1 Chemokine (C-X-C motif) ligand 1 purified Neutralizing R&D Systems 
anti CXCR2 Chemokine (C-X-C motif) receptor 
2 
purified FC R&D Systems 
anti CXCR4 Chemokine (C-X-C motif) receptor 
4 
PE FC BD Biosciences 
anti F4/80 Macrophages APC FC eBiosciences 
anti Gr-1 
(Ly6C and 
Ly6G) 
Neutrophiles and one subset of 
mouse Monocytes 
APC, PerCP FC eBiosciences 
anti Ly6G 1A8 Neutrophils purified Depleting BioXCell 
anti Mac2 Monocytes, Macrophages purified IF Cedarlane 
anti mouse 
serum 
Control serum - Control Accurate 
Chemical 
anti mouse 
thrombocyte 
serum 
Mouse thrombocytes - Depleting Accurate 
Chemical 
anti rabbit 
IgG 
Rabbit IgG FITC FC Sigma-Aldrich 
anti rat IgG Rat IgG FITC FC eBiosciences 
anti rat IgG Rat IgG FITC IF Sigma-Aldrich 
IgG2A rat - Isotype Isotype R&D Systems 
FC: Flow Cytometry; IF: Immunofluorescence; IVM: Intravital Microscopy 
 
 
 
 23 
 
2 Material and Methods 
Table 7: Antagonists 
Antagonist Type Target 
AMD3100 Small molecule Chemokine (C-X-C motif) receptor 4 
DAPTA Peptide Chemokine (C-C motif) receptor 5 
J113863 Small molecule Chemokine (C-C motif) receptor 1 
KF 38789 Small molecule P-Selectin 
RS504393 Small molecule Chemokine (C-C motif) receptor 2 
SB225002 Small molecule Chemokine (C-X-C motif) receptor 2 
 
2.1.4 Mice 
Table 8: Mouse strains 
Gene Name Abbreviation Backround Description of transgene 
Wildtype Bl6 wt C57/Bl6 None 
Apolipoprotein E Apoe C57/Bl6 Targeted mutation 
(Knock-out) 
Chemokine (C-C 
motif) receptor 1 
Ccr1 C57/Bl6 Targeted mutation 
(Knock-out) 
Chemokine (C-C 
motif) receptor 2 
Ccr2 C57/Bl6 Targeted mutation 
(Knock-out) 
Chemokine (C-C 
motif) receptor 5 
Ccr5 C57/Bl6 Targeted mutation 
(Knock-out) 
Chemokine (C-X3-C) 
receptor 1 
Cx3cr1 C57/Bl6 Targeted mutation (GFP 
reporter Knock-in) 
Chemokine (C-X-C 
motif) receptor 2 
Cxcr2 Balb/c Targeted mutation 
(Knock-out) 
Chemokine (C-X-C 
motif) receptor 4 
Cxcr4 C57/Bl6 Targeted mutation 
(Knock-out) 
Lysozyme M Lysm C57/Bl6 Targeted mutation (GFP 
reporter Knock-in) 
Low density 
lipoprotein receptor 
Ldlr C57/Bl6 Targeted mutation 
(Knock-out) 
 
Wild-type C57Bl/6 mice were obtained from Janvier (Chassal, France) whereas mice 
deficient for Apolipoprotein E (Apoe-/-) or Low density lipoprotein receptor (Ldlr-/-) were 
purchased from either Jackson Laboratory (Bar Harbor, USA) or Charles River (Wilmington, 
USA). Mice deficient for different chemokine receptors were all received from the in-house 
animal facility of the University Hospital Aachen. All strains used are summarized in Table 8 
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and were backcrossed for at least ten generations to the background stated in Table 8. All 
mice strains deficient for a chemokine receptor or bearing green fluorescent reporter for 
Lysozyme M are furthermore deficient for Apolipoprotein E. 
 
2.2 Methods 
2.2.1 Biomolecular Methods 
Genotyping of mice used from in-house breeding was carried out according to laboratory 
specific standard operating protocols (SOP). DNA was obtained by isolation from tail tissue 
using protease digestion and the BioSprint 15 System (Quiagen, Hilden, Germany). 
Determining mRNA expression levels in cells as well as in tissues is a widely used method to 
investigate effects and changes within these cells especially after a specific treatment. Even 
though this methodology can give a hint on changes in cell physiology, one has to be aware 
that mRNA does not necessarily correspond to protein expression thus the physiological 
relevance has to be further characterized by complementary methods. 
 
2.2.1.1 RNA Isolation 
Dependent on cell number, RNA from sorted peripheral neutrophils or monocytes (2.2.2.2) 
was isolated using either the RNeasy Mini Kit or the RNeasy Micro Kit (both Qiagen, Hilden, 
Germany). Isolation was followed by digestion of genomic DNA using the RNase-free DNase 
set (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. 
2.2.1.2 RNA Quantification 
RNA concentration was determined by measuring the absorbance at 260 nm (A260) in a 
spectrophotometer. The absorbance at 280 nm was also measured to estimate DNA and 
RNA purity. Pure DNA or RNA has an A260/A280 ratio of 1.8-2.0 at pH 7.0. 
2.2.1.3 Reverse Transcription 
After determination of the RNA amount, up to 2μg total RNA were reverse-transcribed at 
37°C for 1h into cDNA using the M-MLV RT Kit (Promega, Madison, WI, USA) and random 
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hexamer primers (Fermentas, St. Leon Rot, Germany). 20ng of cDNA were assessed in the 
real-time PCR reaction. 
5µl 5x reverse transcription buffer 
0.5µl dNTP mix (20mM each) 
1µl 10µM random hexamer primer 
1µl reverse transcriptase enzyme 
up to 2μg template RNA 
H2O to a final volume of 25μl 
2.2.1.4 Real-time PCR 
For estimating relative expression of mRNA within different samples, real time PCR has been 
performed utilizing the housekeeping gene glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as reference gene. A detailed list of oligonucleotides can be found in Table 5. 
2μl cDNA or H2O 
13µl 2xQuantiTect SYBR Green PCR Master Mix 
forward primer to a final concentration of 0.5µM 
reverse primer to a final concentration of 0.5µM 
RNase free water to final volume of 25µl 
Program for real-time PCR: 
1. Initial activation  95°C, 15 min 
2. Denaturation  94°C, 15 sec 
3. Annealing   58°C, 30 sec 
4. Elongation   72°C, 30 sec 
5. Plate read 
   repeat steps 2-5 45 times 
Relative mRNA expression level of gene of interest compared to a control was calculated 
using 2-ΔΔct method.146 
2.2.1.5 PCR Array 
Employing RT2 Profiler PCR Array (SABiosciences, Frederick, USA) expression of 84 genes 
encoding chemokines and their receptors could be investigated. 
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RNA of cells obtained from fluorescence activated cell sorting (FACS) (2.2.2.2) was isolated as 
described above (2.2.1.1). Using the RT2 First Strand Kit (SABiosciences, Frederick, USA) 
cDNA has been generated and checked for quality and efficiency of reverse transcription by 
RT2RNA QC PCR Array. In case the quality of cDNA met the demands RT2 Profiler PCR Array 
for mouse chemokines and receptors could be performed. All steps were carried out 
following manufacturer´s instructions. 
 
2.2.2 Protein Assays 
 
2.2.2.1 Flow Cytometry 
Flow cytometry is a method used for cell characterization and quantification. By passing an 
argon laser the single cells within a fluid stream scatter and fractionize the laser light thus 
generating a specific fingerprint of the cell including size (forward scatter) and granularity 
(side scatter). By employing fluorescently labeled antibodies, cells can be further 
characterized by their expression of marker proteins on the surface. A detailed list of 
antibodies used for flow cytometry is to be found in Table 6. 
Staining of single cell suspensions of blood, bone marrow or spleen for flow cytometric 
analyses was conducted using combinations of antibodies (1:100) in 50µl of a 1:1 mixture of 
Hank´s complete and FACS staining buffer as indicated in the result section. Before staining 
the cells for 20min on ice, red blood cell lysis has been performed at room temperature 
using an appropriate volume of lysis buffer. Cells were washed with Hank´s complete and 
directly analyzed by flow cytometry using a FACSCantoII (BD Biosciences, Franklin Lakes, 
USA). For intracellular staining, compounds from the BrdU Flow Kit (BD Biosciences, Franklin 
Lakes, USA) containing paraformaldehyde (PFA) and saponin have been utilized for fixation 
and permeabilization according to the manufacturer instructions. Absolute cell numbers 
have been assessed by using CountBright™ absolute counting beads (Invitrogen, Carlsbad, 
USA). 
Data were analyzed with FlowJo Software (Tree Star Inc, Ashland, USA). In case the 
expression level of a protein or receptor was of interest, geometrical mean fluorescence 
intensity subtracted by the fluorescence minus one (FMO) control was calculated. 
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2.2.2.2 Fluorescence Activated Cell Sorting (FACS) 
In a more advanced setup, cells can be separated by their specific characteristics mentioned 
before which is called fluorescence activated cell sorting (FACS). Cells obtained by this 
method can be used for further analysis and experimentation such as RNA isolation (2.2.1.1) 
or adoptive transfer experiments (2.2.3.4). 
Cells were labeled with specific sets of antibodies as described previously (2.2.2.1). Directly 
after staining samples were processed using the FACSAria (BD Biosciences, Franklin Lakes, 
USA) cell sorter. 
2.2.2.3 Enzyme-linked immunosorbent assay (ELISA) 
The enzyme-linked immunosorbent assay (ELISA) is an easy method to detect and quantify 
proteins such as cytokines or chemokines within nearly every type of fluid e.g. serum, cell 
culture supernatant or lavage. 
For this study, different ELISA systems such as Quantikine or DuoSet (both R&D Systems, 
Minneapolis, USA) or Instant ELISA (BenderMedSystems, Vienna, Austria) have been used 
depending on availability for diverse readouts. All systems based on the principal of a 
sandwich ELISA and have been performed according to manufacturer instructions. ELISAs 
were measured at a wavelength of 450nm with the plate reader Infinite M200 and evaluated 
via XFluor™ Software (both Tecan, Crailsheim,Germany). 
2.2.2.4 Immunohistochemistry 
The extent of atherosclerosis was assessed by staining of aortic roots and thoracoabdominal 
aortas by staining for lipid depositions with oil-red-O (Sigma-Aldrich, St. Louis, USA), 
followed by quantification by computerized image analysis (Diskus Software, Königswinter, 
Germany) and Leica Qwin Imaging software (Leica Ltd, Cambridge, UK). Oil-red-O staining 
was performed on 5μm transversal sections through the heart and the aortic roots or on 
thoracoabdominal aorta, which was opened longitudinally. Sections or thoracoabdominal 
aortas were incubated in 0.5% oil-red-O solution for 30min. The percentage of lipid 
deposition was calculated by dividing the stained area by the total surface. 
Collagen content has been evaluated by performing Sirius red staining. Frozen sections of 
aortic root were washed with PBS for at least 5 minutes, put into Sirius red staining solution 
for 1h and 0.01N hydrochloric acid for additional 2min. After performing an ascending 
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ethanol series sections could be analyzed for collagen. Using a polarizing microscope larger 
collagen fibres appear bright yellow or orange and the thinner ones, including reticular 
fibres, are visible in green. 
2.2.2.5 Immunfluorescence 
To define monocyte/macrophage amount in atherosclerotic plaque area, frozen sections of 
aortic roots were washed with PBS for at least 5min followed by an overnight incubation 
with a 1:400 dilution of anti Mac-2 antibody at 4°C. After incubation with secondary FITC 
conjugated antibody for 30min at room temperature sections have been analyzed using a 
Leica DMLB fluorescence microscope and charge couple device (CCD) camera. 
Furthermore TUNEL staining has been performed facilitating In Situ Cell Death Detection Kit, 
TMR red (Roche, Basel, Switzerland) to assess the number of apoptotic/necrotic cells within 
aortic root sections. The assay uses an optimized terminal transferase (TdT) to label free 
3’OH ends in genomic DNA with TMR-dUTP. 
2.2.2.6 Myeloperoxidase (MPO) Assay of lung tissue 
Lung tissue of mice was cut into small pieces and homogenized in 0.02M K+ buffer (10ml per 
0.5g) using ultrasound. After centrifugation the cell pellet was resuspended in 0.05M K+ 
buffer with 0.5% Hexadecyltrimethylammonium bromide and 2 repeated freeze-thaw cycles 
with liquid nitrogen have been performed. Cell debris were centrifuged and supernatants 
were kept and subsequently tested for MPO activity by spectrophotometry using enzyme-
specific substrates as described.147 
 
2.2.3 Animal Experiments 
All animal experiments were approved by the “Landesamt für Natur, Umwelt und 
Verbraucherschutz” North Rhine-Westphalia and carried out in accordance with the 
guidelines for animal experimentation. 
 
2.2.3.1 Mouse model of atherosclerosis 
Mice deficient of Apolipoprotein E as well as different chemokine receptors (Table 8) were 
fed normal chow or, starting at 8 weeks of age, an atherogenic diet containing 21% fat 
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(Altromin, Lage, Germany) for either 4 or 8 weeks. The time of high fat diet depended on the 
experimental setup. For studies on the role of neutrophils in atherosclerosis mice obtained 
high fat diet for 4 weeks whereas for monocyte studies 8 weeks of high fat diet were used. 
To estimate the extent of atherosclerosis, hearts and aorta were harvested after in situ 
perfusion and fixation with 4% PFA followed by staining for lipid deposition with Oil-red-O 
(2.2.2.4). If aortas were harvested for analysis by flow cytometry mice were flushed with PBS 
only. 
The relative content of monocytes and macrophages was determined by Mac-2 
immunofluorescence staining of aortic root sections (2.2.2.5). Collagen deposition was 
measured by Sirius red staining (2.2.2.4). Furthermore apoptotic/necrotic cells were 
assessed using TUNEL assay (2.2.2.5) 
2.2.3.2 Bone marrow transplantation 
Bone marrow transplantation is a useful tool to generate bone marrow chimeras. Therefore 
8 weeks old recipient mice have been treated with an ablative dose of whole-body 
irradiation (2x6 Gy). After transplantation of hematopoietic stem cells (2,5x106) by tail vein 
injection, mice were reconstituted for 4 weeks before they have been put on high fat diet. 
Animals, deficient for CXCR2 breed poorly thus it is impossible to get enough animals for a 
groupsize to be statistically powerful. Furthermore, mice deficient for CXCR2 are not crossed 
into an atherosclerotic background. For that reason femurs and tibias were aseptically 
removed from donor Cxcr2-/- as well as wt control mice. Marrow cavities were flushed and 
single cell suspensions prepared. Donor cells (2,5x106) were administered to Ldlr-/- mice. 
In contrast, CXCR4 deficient mice are intrauterine lethal thus only mating of heterozygous 
animals is possible. Embryos had to be harvested 14 days after fertilization and after 
estimating the correct genotype liver cells could be transplanted to Ldlr-/- mice. 
2.2.3.3 Blood drawing, animal dissection and organ preparation 
After short anesthesia with Isofluran (Abbott, Wiesbaden, Germany) blood of living mice was 
drawn through the retro-orbital plexus and collected in EDTA tubes (Sarstedt, Nümbrecht, 
Germany). 
 30 
 
2 Material and Methods 
In case mice had to be sacrificed they were anesthetized by injection of 6-8mg Xylazin and 
90-120mg Ketamin per kg body weight and exsanguinated by heart puncture. Whole blood 
was kept for serum separation. Mice were flushed with 10ml of PBS first and depending on 
experimental setup furthermore rinsed with 10ml of 4% PFA. Aortas were removed and 
either kept on ice in RPMI1640 + 10% FCS or used for Oil-red-O staining after overnight-
fixation in 4% PFA. For flow cytometry analysis, whole aorta has been digested with 
0.25mg/ml Liberase in RPMI1640 + 10% FCS medium. Lysed aortas were then put through a 
cell strainer and stained with antibodies for further flow cytometry analsysis. If bone marrow 
lavage fluid had to be examined, bones were flushed with 500µl RPMI1640 + 10% FCS, cells 
were centrifuged for flow cytometry and supernatant has been used for further analysis by 
ELISA. Spleens were mashed through a cell strainer and after red blood cell lysis 
subsequently used for antibody labeling. 
2.2.3.4 Adoptive cell transfer 
The return of donor cells into recipient mice is commonly named with adoptive transfer. The 
beauty of this methodology is the possibility to study the behavior of cells of a specific 
phenotype within a normalized environment. Thus, in vivo migration of monocytes lacking 
one of the chemokine receptors that have been investigated could be analyzed. 
Employing cell sorting (2.2.2.1/2.2.2.2), inflammatory monocytes from bone marrow were 
isolated. After labeling the monocytes with 5µM carboxyfluorescein succinimidyl ester 
(CFSE) in RPMI1640 + 10% FCS for 10min at 37°C 1.2x106cells were adoptively transferred by 
tail vein injection to Apoe-/- mice fed a high fat diet for one month. One day after transfer, 
aortas and hearts of recipient mice were collected for further analysis. 
2.2.3.5 Mobilization assays 
Besides the recruitment of leukocyte subsets to sites of inflammation, involvement of 
chemokine receptors in hemostasis should be addressed. For that reason, chemokines such 
as rmCXCL1 (KC) have been injected intravenously at 40µg/kg. Afterwards blood was drawn 
by puncturing retroorbital plexus and mice were sacrificed to harvest bones, spleen and 
lung. Thus, mobilization of cells from bone marrow, spleen or lung to circulation could be 
monitored by FACS analysis or MPO measurement (2.2.2.6). 
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2.2.3.6 In vivo depletion of leukocyte subsets 
Either to obtain insights into the specific role of leukocyte subsets or to improve possible 
readouts from different imaging techniques, specific in vivo depletion of cell subsets can be 
performed. 
Monocytes can be easily eradicated from circulation by intravenous injection of 200µl 
undiluted chlodronate loaded liposomes (Nico van Rooijen, Amsterdam, The Netherlands). 
Depletion of Neutrophils has been performed by intraperitoneal injection of 100µg anti 
mouse Ly6G antibody (1A8) up to twice a week. Moreover platelet number was severely 
reduced by intraperitoneal injection of 50µl anti platelet serum. Dependent to the 
experimental setup application schemes varied and are stated separately in the results 
section. 
As long as there is no possibility available to specifically deplete only one of both monocyte 
subsets in vivo we established a protocol of cyclophosphamide injection at regular intervals. 
Thus proliferation of hematopoietic stem cells had been blocked leading to a remarkable 
reduction in leukocytes mobilized from bone marrow. Utilizing adoptive transfer 
methodology (2.2.3.4) and cell sorting (2.2.2.2), whole blood of donor mice lacking only one 
specific cell subset has been used to reconstitute leukopenic mice. 
2.2.3.7 Intravital microscopy 
Neutrophil rolling, adhesion and extravasation in the cremaster muscle were observed by 
intravital microscopy in Lysmegfp/egfpApoe-/- mice depleted of monocytes by chlodronate 
liposome injection to obtain mice with fluorescent neutrophils only. Inflammation was 
initiated by local injection of rmTNF (50ng/scrotum) and the cremaster muscle was 
exteriorized for microscopic observation 4h later. Rolling neutrophil flux was determined as 
the number of neutrophils passing a reference line perpendicular to blood flow within 30 
seconds. Neutrophils were considered adherent when no rolling was observed for at least 30 
seconds. Specific chemokine receptor antagonists according to table 4 were injected i.p. 1h 
prior to stimulation at 5mg/kg body weight (1mg/kg for DAPTA). For analysis of neutrophil 
interactions with the external carotid artery, Lysmegfp/egfpApoe-/- mice were fed a high fat diet 
for four weeks. For luminal detection of chemokines presented on the endothelium, 50µl of 
Protein G Fluoresbrite® YG Microspheres (Polysciences) were coupled to 50µg of polyclonal 
antibodies to CCL2, CCL3, or CCL5 or an IgG control (Table 6). Beads and antibodies were 
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reacted for 30min at room temperature, washed twice and subsequently injected i.v. into 
mice after exposure of the external carotid or the cremaster muscle. Antibody/bead 
complexes were allowed to circulate for 15min and immobilized complexes were detected. 
2.2.3.8 Model of acute peritonitis 
The model of acute peritonitis serves as a microvascular model to examine the recruitment 
of cells towards an inflammatory stimulus. By employing mice lacking one chemokine 
receptor or usage of specific chemokine receptor antagonists, involvement of targeted 
receptors in cell recruitment can be investigated. 
Mice deficient for a chemokine receptor were injected intraperitoneally with 50ng rmTNF in 
sterile PBS. After 4h, mice were sacrificed and the peritoneal cavity was lavaged. The 
number of infiltrated neutrophils was analyzed using flow cytometry. Specific chemokine 
receptor antagonists were instilled intraperitonealy 1h prior to administration of rmTNF as 
described for intravital microscopy above. 
2.2.3.9 In vivo Two-Photon microscopy 
Mice were placed in supine position and the left common carotid artery including the 
bifurcation and part of the internal branch were surgically exposed. Exposed areas were kept 
moist with saline at all time during the experiment. Exposed arteries were imaged using a 
LaVision Biotec Trimscope multiphoton system (LaVision Biotec GMBH, Bielefeld, Germany). 
In short, the LaVision Trimscope was used in single beam mode and coupled into an Olympus 
BX61WI microscope with an Olympus 20X NA 0.95; water dipping objective (Olympus GMBH 
Hamburg, Germany). Two-photon excitation was achieved using a pulsed Ti-Sapphire laser 
(MaiTai HP, Spectra Physics, Mountain View, USA) tuned to 830 nm for visualization of 
second Harmonic Generation (SHG) signal of collagen, Green Fluorescent Protein (GFP), and 
auto fluorescent signal originating from the elastic laminae. Emitted fluorescent signals were 
detected with two photomultiplier tubes (PMTs) tuned to corresponding parts of the 
emission spectra: SHG, 453-497 nm (PMT 1); GFP, 500-550 nm (PMT 2); auto fluorescence 
signal of elastin was detected in both PMT’s. Series of subsequent xy-sections (180x180 
pixels) were obtained over time at an acquisition rate of 6Hz using the Inspector Pro 4.0.43 
acquisition software (LaVision Biotec GMBH). After image acquisition the obtained time 
series were analyzed and only xy-sections acquired at comparable z-position and without 
severe motion artifacts (due to heart- and respiration cycle), were selected for further 
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analyses. Overall image quality was improved by resizing the pixel matrix 2.5 times using a 
bilinear scaling technique. Furthermore, 2D Gaussian weigthed filtering was performed to 
improve the signal-to-noise ratio and thus overall image quality. All image processing was 
performed using Image-Pro 3D analyzer 7.0 (Media Cybernetics, Silver Spring, USA).  
 
2.2.4 Statistics 
All continuous data are expressed as mean±SD. Statistical calculations were performed using 
GraphPad Prism 5 (GraphPad Software Inc.). After calculating for normality by D`Agostino 
Pearson omnibus test either unpaired Student’s t-test, One-way ANOVA with Newman-Keuls 
multiple comparison or nonparametric tests such as Mann-Whitney test, or Kruskal-Wallis 
test with posthoc Dunn test were used. *Indicates a p-value < 0.05. 
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3 Results 
3.1. Role of neutrophils during the onset of atherosclerosis 
3.1.1 Hypercholesterolemia induces neutrophilia 
Hypercholesterolemia has been reported to affect counts, phenotype, and function of 
peripheral blood leukocyte subsets.96,148,149 Therefore, we analyzed circulating neutrophil 
counts in Apoe-/- mice fed a high-fat diet (HFD). In contrast to Apoe-/- mice receiving chow, 
Apoe-/- mice fed a HFD developed both leukocytosis and neutrophilia (Figure 6A). It has 
previously been suggested that the number of circulating neutrophils positively correlates 
with the degree of atherosclerosis and atherosclerosis-related diseases.150,151 In line, we 
found that plaque sizes in Apoe-/- mice with early atherosclerotic lesions highly correlated 
with circulating neutrophil numbers (Figure 6B/C). 
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Figure 6: High-fat diet induced neutrophilia correlates with early atherosclerotic lesion formation. A: Leukocyte (CD45+) 
and neutrophil (CD45+CD11b+Gr1+CD115-) counts in peripheral blood of Apoe-/- mice with or without HFD for 4 weeks. n=6. 
Mann-Whitney. B: Quantification of atherosclerotic lesion size of aortic roots in Apoe
-/-
 mice with or without HFD as well as 
representative images. Horizontal lines indicate means. Mann-Whitney. C: Pearson correlation between lesion size and 
peripheral neutrophil counts in Apoe-/- mice having received HFD. 
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3.1.2 Hyperlipidemia interferes with neutrophil homeostasis 
We next aimed at elucidating mechanisms underlying HFD-mediated neutrophilia. 
Neutrophil homeostasis is regulated at various levels including granulopoiesis, mobilization 
from the bone marrow as well as apoptosis and subsequent clearance.99  
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Figure 7: High fat diet-induced neutrophilia is based on stimulated granulopoiesis and mobilization from the bone 
marrow and reduced clearance. A: Absolute numbers of bone marrow neutrophils (left) and of bone marrow neutrophils 
undergoing mitosis (middle) as well as serum G-CSF levels in Apoe-/- mice with or without HFD (right). n=8. Unpaired t-test. 
B: Expression of CXCR2 on bone marrow neutrophils of Apoe-/- mice with or without HFD (left and middle) and serum levels 
of mCXCL1 in Apoe-/- mice receiving HFD or not (right). n=8. Unpaired t-test. C: Number of Annexin V+ (AnV+) neutrophils in 
the bone marrow (left), CXCR4 expression of circulating neutrophils (middle), and CXCL12 concentrations in bone marrow 
lavages (right) of Apoe-/- mice with or without HFD. n=8. Unpaired t-test. MFI, mean fluorescence intensity. 
 
Therefore we initially assessed the fraction of mitotic neutrophils in the bone marrow, 
where neutrophil counts were also elevated (Figure 7A). Cell cycle analysis using the DNA-
intercalating dye propidium iodide revealed that the number of myeloid cells in S/M phase 
was increased in mice on HFD indicating stimulated granulopoiesis. Accordingly, serum G-
CSF levels were found to be elevated (Figure 7A). Major inducers of G-CSF are TNF as well as 
IL-17, both of which were at higher concentrations in the serum of mice receiving HFD (data 
not shown), suggesting a contribution of both cytokines to enhanced G-CSF levels and 
subsequent granulopoiesis. The CXCR2-CXCL1 and CXCR4-CXCL12 axes are crucially involved 
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in neutrophil mobilization and clearance, respectively. 99,112,149,152 Together with higher 
serum levels of mCXCL1, increased expression of CXCR2 on bone marrow neutrophils in mice 
receiving HFD (Figure 7B) suggests that neutrophils are more readily mobilized from the 
bone marrow in hypercholesterolemia. In line, CXCL12, which exerts a retention signal for 
bone marrow neutrophils152, was reduced in the bone marrow lavage of mice receiving HFD 
(Figure 7C) thus favouring mobilization of bone marrow neutrophils. In addition, CXCL12 is 
an important signal for the clearance and recruitment of aged neutrophils from the 
circulation to the bone marrow.111,152 Hence, reduced numbers of apoptotic neutrophils in 
the bone marrow of mice on HFD in association with lower levels of CXCL12 in bone marrow 
lavage fluids (Figure 7C) suggest a reduced neutrophil clearance under HFD. Collectively, 
these data indicate that a disturbance of the CXCR2-mCXCL1 and the CXCR4-CXCL12 axes 
contributes to HFD-induced neutrophilia. Moreover, a large pool of marginated neutrophils 
can be found in the lung circulation and mobilization from this location may contribute to 
HFD-induced neutrophilia. As MPO concentration and the number of neutrophils in 
enzymatically-digested lungs were not affected by HFD (Figure 8), such mechanism seems 
unlikely. 
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Figure 8: Neutrophil count and MPO measurement. Absolute numbers of neutrophils in enzymatically-digested lungs (left) 
and MPO activities in lung homogenates (right) in Apoe-/- mice with or without HFD. n=5. Mann-Whitney. 
 
3.1.3 Neutrophils infiltrate large arteries 
Previous studies have reported the presence of neutrophils in human and murine 
atherosclerotic lesions. 47,153,154 The mechanisms by which neutrophils promote 
atherogenesis have, however, not been systemically investigated. To address the 
involvement of neutrophils at various stages of atherosclerotic lesion formation, we first 
investigated the prevalence of neutrophils in the aorta at several time points following 
commencement of HFD. FACS analysis of enzymatically-digested aortas allowed for 
identification and quantification of CD45+CD11b+Gr1+F4/80-CD115- neutrophils. While only 
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few neutrophils were detected at initiation of HFD, neutrophils represented 14% of CD45+ 
cells in the aorta after one month of HFD, a proportion, which subsequently decreased 
(Figure 9A). 
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Figure 9: Neutrophils predominantly infiltrate arteries in early stages of atherosclerosis. A: Prevalence of 
CD45+CD11b+Gr1+F4/80-CD115- neutrophils in enzymatically-digested aortas of Apoe-/- mice at different time points 
following commencement of HFD. n=5. B: Adhesion of neutrophils to the external carotid artery in monocyte-depleted 
Lysmegfp/egfpApoe-/- mice after four weeks of HFD. C: Detection of Ly6G+ neutrophils in aortic root lesions of Apoe-/- mice 
after one month of HFD. D: In-vivo 2-photon microscopic detection of neutrophils in monocyte-depleted Lysmegfp/egfpApoe-/- 
mice after four weeks of HFD. Cells adherent to the external carotid artery were tracked over 30 minutes. 
 
Confirmation for the early infiltration of neutrophils comes from intravital microscopic 
observations of the external carotid artery of monocyte-depleted Lysmegfp/egfpApoe-/- mice. In 
this model only neutrophils are fluorescent (Figure 10) and were clearly found to adhere to 
the lumen of the external carotid artery (Figure 9B). Confirming previous reports47,153, we 
further detected neutrophils by immunohistochemical analyses of aortic roots of Apoe-/- 
mice having received HFD for four weeks by staining for the neutrophil-specific marker Ly6G 
(Figure 9C).These data suggest a transluminal rather than a transadventitial route of arterial 
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neutrophil infiltration. This notion is further corroborated by observations using intravital 2-
photon microscopy of monocyte-depleted Lysmegfp/egfpApoe-/- mice. Following adhesion, 
neutrophils spread out and migrate into a subendothelial location (Figure 9D). 
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Figure 10: Depletion of monocytes after injection of chlodrodrante liposomes. Neutrophils and monocytes of 
Lysmegfp/egfpApoe-/- are green fluorescent. Representative dot plots show that monocytes, supposed to be 
CD45+CD11b+CD115 are nearly absent after injection of chlodronate liposomes compared to injection of PBS loaded 
liposomes. 
 
3.1.4 Neutrophils are crucial during onset of atherosclerosis 
To link aortic neutrophil infiltration to atherogenesis more specifically, we selectively 
depleted Apoe-/- mice of neutrophils (Table 9) at various time points after initiation of HFD. 
By this approach we found a significant reduction of the degree of atherosclerotic lesion 
formation of aortic roots (Figure 11) at early time points only. Specifically, depletion of 
neutrophils during the first four weeks of HFD reduced atherosclerotic lesions by 49%, 
whereas no effect was seen when mice were rendered neutropenic after three or eleven 
months of HFD (Figure 11). 
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Figure 11: Depletion of neutrophils during early stages of atherosclerosis reduces lesion formation. Atherosclerotic lesion 
sizes in aortic root sections of Apoe-/- mice either with intact white blood counts or being neutropenic. Neutropenia was 
induced during the last four weeks of HFD. *Indicates significant changes, Mann-Whitney. 
 
Table 9: Blood cell counts/ml after neutrophil depletion 
 neutrophils Gr1+ Gr1- T-lymphocytes B-lymphocytes 
Intact WBC 9.7x105 
+/- 2.2x105 
3.7x105 
+/- 0.9x105 
2.2x105 
+/- 0.3x105 
1.9x106 
+/- 0.4x106 
2.3x106 
+/- 0.5x106 
neutropenic 0.8x105 
+/- 0.2x105 
3.4x105 
+/- 0.6x105 
2.2x105 
+/- 0.2x105 
1.8x106 
+/- 0.2x106 
2.2x106 
+/- 0.4x106 
 
3.1.5 Neutrophils express a variety of chemokine receptors 
Addressing the question whether neutrophils express different chemokine receptors that 
could be involved in their recruitment to atherosclerotic lesions we performed a PCR array 
with FACS sorted circulating neutrophils from mice either put on HFD for one month or fed a 
normal chow. As the array had been performed to receive some indications for possible 
candidate genes, the results were further corroborated by real-time PCR for single genes of 
interest as well as flow cytometry to additionally prove expression on protein level. 
Transcriptional changes could be observed for Cxcr2 as well as Cxcr4. Both genes showed an 
increased expression in bone marrow neutrophils under hypercholesterolemic conditions. In 
circulating neutrophils no differences could be observed and mRNA of two genes was not 
detectable supporting the assumption that once the neutrophil is mobilized to the 
circulation it is more or less transcriptionally inactive. However, on protein level, only 
expression of CXCR2 on bone marrow neutrophils was increased under hyperlipidemia 
compared to normal chow as already shown under 3.1.2. No changes could be observed for 
any other chemokine receptors investigated (Figure 12). 
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Figure 12: HFD induced alterations of chemokine receptor expression by neutrophils. Fold change of mRNA expression in 
circulating and bone marrow neutrophils from mice fed normal chow compared mice that received HFD (left). Right graph 
summarizes the same experimental setup for protein expression. *Indicates significant changes of expression level under 
hyperlipidemia compared to normal chow. n=5. Mann-Whitney. nd=not detectable. 
 
3.1.6 Arterial neutrophil recruitment depends on CCR1, CCR2, CCR5 and CXCR2 
To elucidate the involvement of chemokine receptors in neutrophil accumulation in the 
aorta, we quantified neutrophil counts in digested aortas of atherosclerotic mice with 
deficiency in Ccr1, Ccr2, and Ccr5. The involvement of CXCR2 and CXCR4 was studied in bone 
marrow chimeras. Interestingly, Ccr1-/-Apoe-/-, Ccr2-/-Apoe-/-, Ccr5-/-Apoe-/-, and Cxcr2-/-˃Ldlr-/- 
mice exhibited reduced aortic neutrophil numbers compared to Apoe-/- or WT˃Ldlr-/-, 
respectively (Figure 13A). Cxcr4-/-˃Ldlr-/- mice, on the other hand, displayed higher neutrophil 
counts (Figure 13A), likely attributable to increased peripheral neutrophil counts in this 
model.47 To further corroborate our findings, we employed a model of intravital microscopy 
using short-term treatment with specific chemokine receptor antagonists, hence not 
skewing peripheral neutrophil counts. Utilizing monocyte-depleted Lysmegfp/egfpApoe-/- 
neutrophil-reporter mice, we could validate the involvement of CCR1, CCR2, CCR5, and 
CXCR2 in neutrophil adhesion (Figure 13B) to large arteries. This contrasts to the reported 
recruitment pattern of neutrophils, which have been described to primarily employ CXCR2 
and in some circumstances CCR2 for tissue infiltration.155,156 
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Figure 13: Neutrophils infiltrate aortas via CCR1, CCR2, CCR5, and CXCR2. A: Aortic neutrophil content assessed by FACS 
analysis of digested aortas in atherosclerotic mice lacking indicated chemokine receptors and having received HFD for four 
weeks. Neutrophil numbers in control animals (shaded) are set to 100%. n=5-7. Kruskal-Wallis test with posthoc Dunn test. 
B: Adhesion of neutrophils to carotid arteries of monocyte-depleted Lysmegfp/egfpApoe-/- mice fed a HFD for one month and 
having received a single dose of indicated chemokine receptor antagonist 1h prior to experimentation. Representative 
images of neutrophils adhering to the luminal side of the external carotid artery in Apoe-/- mice pretreated with indicated 
chemokine receptor antagonists. *Indicates significant difference compared to respective control. n=4-6. Kruskal-Wallis test 
with posthoc Dunn test. C: Peritoneal neutrophil accumulation in response to rmTNF (50 ng/mouse) in atherosclerotic mice 
receiving chemokine receptor antagonists 1h before rmTNF application. *Indicates significant difference compared to 
respective control (shaded). n=5-7. Kruskal-Wallis test with posthoc Dunn test. D: Adhesion (left) and extravasation (right) 
of neutrophils in cremasteric postcapillary venules of monocyte-depleted Lysmegfp/egfpApoe-/- mice following intrascrotal 
(i.s.) challenge with rmTNF (50 ng/scrotum). Chemokine receptor antagonists were injected i.p. 1h prior to rmTNF 
treatment. *Indicates significant difference compared to vehicle control. n=6. Kruskal-Wallis test with posthoc Dunn test. 
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Figure 14: Peritoneal neutrophil infiltration in chemokine receptor deficient mice. Peritoneal neutrophil accumulation in 
response to rmTNF (50 ng/mouse) in atherosclerotic chemokine receptor deficient mice. *Indicates significant difference 
compared to respective control (shaded). n=5-7. Kruskal-Wallis test with posthoc Dunn test. 
 
As these data primarily stem from microcirculatory recruitment models, we compared the 
recruitment of neutrophils to large arteries to postcapillary venous recruitment behaviour. 
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Intraperitoneal challenge of chemokine receptor-deficient atherosclerotic mice (Figure 14) 
or Apoe-/- mice pretreated with chemokine receptor antagonists with rmTNF (Figure 13C) 
confirmed the involvement of CCR2 and CXCR2 in neutrophil extravasation as has been 
reported.155,156 Furthermore, we found CCR2 and CXCR2 to be involved in adhesion and 
extravasation of neutrophils in the cremaster muscle of monocyte-depleted 
Lysmegfp/egfpApoe-/- mice locally injected with rmTNF (Figure 13D). Taken together, these data 
suggest a microvascular recruitment pattern that largely differs from that in large arteries 
such that CCR1 and CCR5 seem to have important roles in arterial but not venous 
recruitment. 
 
3.1.7 Endothelium in micro- and macrocirculation presents different chemokines  
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Figure 15: Differential chemokine presentation between cremaster venule and carotid artery. A: Immobilization of G-
protein coupled fluorescent beads conjugated with IgG or antibodies to CCL2, CCL3, or CCL5 on endothelium of 
postcapillary cremasteric venules B: or the external carotid artery. Representative images are shown for beads coated with 
IgG, anti-CCL2, and anti-CCL5. n=5. 
 
Since the expression of CCR1 and CCR5 was not significantly altered in Apoe-/- mice receiving 
HFD (Figure 12), we consequently hypothesized that the endothelial presentation of CCL3 
and CCL5, both of which interact with CCR1 and CCR5, may differ between the vascular beds. 
Hence, we examined the luminal immobilization of fluorescent beads conjugated with 
antibodies to CCL2, CCL3, or CCL5 in vivo as a measure of locally presented chemokines. 
While CCL2 was clearly detected in the carotid artery and postcapillary venules of the 
cremaster muscle when compared to the respective IgG control, in agreement with the 
involvement of CCR2 in neutrophil recruitment at either site, CCL5 was primarily detectable 
in the carotid artery but not the veins of cremaster muscles (Figure 15A/B). CCL3, on the 
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other hand was not found at either vascular bed. Hence, differential presentation of the 
CCR1 and CCR5 ligand CCL5 may be the underlying cause for the different neutrophil 
recruitment pattern. 
 
3.1.8 Platelet derived CCL5 promotes arterial neutrophil recruitment 
Platelets are a major source for CCL522 and endothelial deposition of CCL5 has recently 
emerged as a therapeutic option.33,42 To dissect the importance of platelets in endothelial 
CCL5 deposition in our model, we selectively depleted platelets (Table 10). Compared to 
control animals, thrombocytopenic mice exhibited lower amounts of CCL5 deposited in 
carotid arteries. This observation was corroborated in mice treated with a P-selectin 
antagonist or an inhibitor of platelet GPIIb/IIIa (ReoPro®), which display reduced CCL5 
deposition (Figure 16A). Similarly, the involvement of platelet-derived CCL5 in arterial 
neutrophil recruitment was further evaluated in platelet-depleted mice, which exhibit 
reduced numbers of neutrophils adhering to the carotid artery (Figure 16B). 
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Figure 16: Deposition of CCL5 within large arteries partially depends on platelets. A: Luminal arrest of G-protein coupled 
fluorescent beads conjugated with antibodies to CCL5 in the carotid artery in mice treated with thrombocyte-depleting 
serum, the respective control, or antagonists to P-selectin or GPIIb/IIIa. n=4-5. *Indicates significant difference compared to 
respective control. Mann-Whitney (left) or Kruskal-Wallis test with posthoc Dunn test (right). B: Number of neutrophils 
adhering to the external carotid artery of monocyte-depleted Lysmegfp/egfpApoe-/- mice treated with platelet depleting serum 
or not. n=4-5. Mann-Whitney. 
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Table 10: Blood cell counts/ml after platelet depletion 
 WBC neutrophils monocytes lymphocytes platelets 
control   
serum 
6.6x106 
+/- 1.6x106 
1,3x106 
+/- 0.3x106 
5,0x105 
+/- 1.1x105 
4.7x106 
+/- 1.2x106 
533x108 
+/- 90x108 
αplatelet 
serum 
6.4x106 
+/- 1.2x106 
1,5x106 
+/- 0.2x106 
4.3x105 
+/- 0.5x105 
4.4x106 
+/- 1.3x106 
0.4x108 
+/- 0.4x107 
 
3.2 Importance of monocytes in atheroprogression 
3.2.1 Hyperlipidemia induces a manifest monocytosis 
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Figure 17: High-fat diet-induced monocytosis is due to increased numbers of Gr1+ monocytes only. A: Representative dot 
plots displaying Monocyte (CD45+CD11b+ Gr1+CD115+) counts in peripheral blood of Apoe-/- mice fed HFD or normal chow. 
B: Whole monocyte counts as well as counts of both monocytic subsets either in blood (upper panel) or bone marrow 
(lower panel). n=8, Student`s t-test. *Indicates significant differences compared to control group (grey). 
 
As reported in the previous section (3.1.1) hyperlipidemia causes a boost in circulating 
leukocyte counts. In addition to the increased neutrophil count, we further investigated 
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changes in monocyte numbers and especially their distinct subsets. Thus we could proof that 
neutrophilia in mice which receiving HFD is accompanied by a manifest monocytosis that is 
caused by increased numbers of Gr1+ monocytes only. In contrast, counts of circulating Gr1- 
monocytes remain unaffected (Figure 17A/B). Similarly, augmented numbers of monocytes 
due to increased counts of Gr1+ monocytes have also been observed in the bone marrow 
(Figure 17B), an observation already published by another group reporting amplified 
proliferation and survival but impaired conversion of Gr1+ to Gr1- monocytes as possible 
reasons for monocytosis under HFD96. Nevertheless a conclusive reason for elevated 
monocyte counts under hyperlipidemia remains elusive. 
 
3.2.2 The CXCR2-CXCL1 (KC) axis is partially responsible for monocytosis 
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Figure 18: HFD differentially affects cytokines involved in monocyte proliferation and mobilization. A: Serum levels of M-
CSF in mice fed a HFD (left) and numbers of proliferating Gr1+ monocytes in bone marrow (right). B: MCP-1 and MCP-3 
serum level in mice receiving either normal chow or HFD C: Protein expression (isotype corrected mean fluorescence 
intensity-MFI) of CXCR2 on both monocyte subsets assessed by flow cytometry. D: Serum CXCL1 level in mice receiving 
either HFD or normal chow. n=8-10, Student´s t-test for cytokine measurements; others n=4-5, Mann-Whitney. *Indicates 
significant differences compared to control group (grey). 
 
To further address the question of how monocytosis evolves under HFD, serum levels of 
cytokines involved in homeostasis have been tested. Thus, an increased macrophage colony 
stimulating factor (M-CSF) level could be detected which may functionally relate to an 
elevation of mitotic Gr1+ monocytes in the bone marrow (Figure 18A). Because the 
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chemokine receptor CCR2 and its ligands CCL1 (MCP-1) and CCL7 (MCP-3) are reported to 
dominate monocyte mobilization from bone marrow under homeostatic as well as 
inflammatory conditions70,84,157 we furthermore assessed the serum concentrations of these 
chemokines. Surprisingly, neither change in MCP-1 nor MCP-3 could be observed in serum 
from mice fed a HFD (Figure 18B), implying the involvement of a different, so far not 
described mechanism underlying hyperlipidemia induced monocytosis. 
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Figure 19: CXCL1 (KC) efficiently mobilizes Gr1+ monocytes from both bone marrow and spleen. Gr1+ monocyte counts in 
blood, bone marrow and spleen 1h after intravenously application of 40µg/kg CXCL1 (KC) into C57/Bl6 mice. n=10, 
Student`s t-test. *Indicates significant differences compared to injection of PBS (white). 
 
When screening for the protein expression of different chemokine receptors which could be 
involved in monocyte mobilization we noted a high CXCR2 expression on Gr1+ monocytes. 
The expression level was thereby clearly higher as compared to the Gr1- monocyte subset 
and moreover increased under hyperlipidemic conditions (Figure 18C). With increased CXCL1 
(KC) levels in the serum of mice fed a HFD (Figure 18D), we consequently hypothesized an 
involvement of the CXCR2-CXCL1 axis in HFD-induced monocytosis. To further corroborate 
this assumption we performed a mobilization assay in which CXCL1 has been injected 
intravenously into C57/Bl6 mice. Indeed mobilization of Gr1+ monocytes not only from the 
bone marrow but also the spleen could be observed (Figure 19). This finding is in line with a 
recent publication describing the spleen as a reservoir for Gr1+ monocytes that can be easily 
mobilized during acute inflammation.85 
Postulating a crucial role of the CXCR2-CXCL1 axis in hyperlipidemia-induced monocytosis we 
daily injected 5µg of an anti CXCL1 antibody or the respective isotype control into Apoe-/- 
mice over 7 days. Blood was drawn before and after antibody application and Gr1+ 
monocytes were quantified. Interestingly, mice that received an anti CXCL1 antibody 
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developed no HFD-induced monocytosis compared to those injected with the respective 
isotype control (Figure 20). 
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Figure 20: Blocking CXCL1 prevents hyperlipidemia-induced monocytosis. 8 week old Apoe-/- mice were fed a HFD for one 
week. Additionally they were daily injected with an antiCXL1 antibody (5µg/mouse) (right) or the respective isotype control 
(left). The numbers of Gr+ monocytes were measured before HFD and afterwards. n=10, Student`s t-test. *Indicates 
significant differences compared to control. 
 
3.2.3 Gr1+ monocytes but not Gr1- monocytes dominate atheroprogression 
Involvement of monocytes in atheroprogression is essential as proved by extensive 
investigations during the past decades. After entering sites of atherosclerosis, monocytes 
differentiate to macrophages and following uptake of oxLDL form foam cells. However, the 
specific role of either monocyte subsets in atherogenesis and –progression as well as the 
precise mechanisms underlying their recruitment are still under discussion and remain to be 
firmly established. Facilitating regular injection of cyclophosphamide to inhibit endogenous 
leukocyte proliferation and mobilization combined with the adoptive transfer of cell sorted 
whole leukocytes lacking either the Gr1+ or the Gr1- monocytes we aimed at elucidating the 
specific roles of monocyte subsets in atherosclerosis. Thus, Apoe-/- mice were fed a HFD for 4 
weeks before they have been treated with cyclophosphamide for another 4 weeks under 
hypercholesterolemic conditions. In total five groups were investigated. Group 0 received 
HFD for 8 weeks thus serving as control. The remaining 4 groups received 100mg/kg 
cyclophosphamide two times a week during weeks 5-8 of HFD. Group I received no leukocyte 
substitution whereas group II obtained whole leukocytes, group III whole leukocytes lacking 
Gr1+ and group IV whole leukocytes lacking Gr1- monocytes. A schematic overview of the 
experimental setup is given in Figure 21. 
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Figure 21: Schematic overview of the experimental setup to investigate the specific role of either monocyte subset in 
atherogenesis. After one month of HFD mice were treated with cyclophosphamide (CPM) to suppress proliferation as well 
as mobilization of myeloid cells from bone marrow. Within different groups either complete leukocytes or white blood cells 
(WBC) lacking the one or the other monocyte subset were subsequently substituted to recipient mice after fluorescence 
activated cell sorting from peripheral blood of donor mice. 
 
Mice treated with cyclophosphamide alone exhibited reduced plaque sizes in aortic root 
sections when compared to control. For mice that additionally received adoptively 
transferred whole leukocytes two times a week, plaque sizes could be restored to an extend 
observed in control mice, confirming the essential role of bone marrow derived leukocytes in 
atheroprogression. By transfer of whole leukocytes lacking the Gr1+ monocyte subset plaque 
sizes were reduced to the same size observed in leukopenic mice whereas this was not the 
case for those animals that received leukocytes without Gr1- monocytes (Figure 22A). This 
finding clearly highlights the role of the Gr1+ monocyte but not of Gr1- subset in 
atheroprogression, a conclusion further supported by the analysis of aortic root sections for 
the prevalence of macrophages by immunfluorescence staining of Mac2+ cells. 
Monocytes/Macrophages were markedly reduced in animals without leukocyte substitution 
and in mice having received leukocytes lacking Gr1+ monocytes (Figure 22B). 
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Figure 22: Impact of Gr1+ and Gr1- monocytes on atheroprogression. A: Quantification of atherosclerotic lesion size of 
aortic roots in Apoe-/- mice as well as representative images. Horizontal lines indicate means. n=8-12, One-way ANOVA with 
Newman-Keuls multiple comparison. *Indicates significant differences. Control plaque size – no treatment (0), Treatment of 
mice with CPM alone (I), transfer of complete WBC twice a week (II), substitution of WBC without Gr1+ monocytes (III), 
substitution of WBC lacking Gr1- monocytes (IV). B: Similar groups stained for Mac2+ cells within sections of aortic roots. 
n=8-12, One-way ANOVA with Newman-Keuls multiple comparison. *Indicates significant differences. 
 
3.2.4 Monocyte subsets differentially effect plaque phenotype 
Beside the question how both monocyte subsets influence atherogenesis and –progression, 
we additionally tried to dissect their role in affecting plaque phenotype. For the model of 
myocardial infarction both subsets have already been described to exhibit different purposes 
thereby influencing composition and reconstitution of infarcted, ischemic tissue.158 To 
elucidate a potential role of either monocyte subset in clearance of necrotic cells we 
performed TUNEL staining of aortic root sections. Only a tendency for an increased amount 
of TUNEL+ cells per section could be detected within sections from animals treated with 
cyclophosphamide alone. However, that difference was significant for the animals receiving 
a WBC substitution lacking Gr1+ monocytes only (Figure 23), implying a potential role of 
those monocytes in clearance of dead cells. Surprisingly, the number of necrotic cells was 
significantly decreased in mice receiving WBC substitution without Gr1- monocytes when 
compared to either cyclophosphamide control group (I) or mice with WBC substitution 
lacking Gr1+ monocytes (IV) (Figure 23). Interestingly, no significant differences could be 
observed in collagen deposition within the atherosclerotic lesions between all groups (Figure 
23). 
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Figure 23: Influence of both monocyte subsets on plaque phenotype. Aortic root sections were stained by TUNEL to assess 
number of necrotic cells (left graph). To quantify collagen content of the atherosclerotic plaque Sirius red stain has been 
performed (right). Control (0), CPM alone (I), whole WBC substitution (II), WBC – Gr1+ substitution (III), WBC – Gr1- 
substitution (IV). n=8-12, One-way ANOVA with Newman-Keuls multiple comparison. *Indicates significant differences. 
 
3.2.5 Chemokine receptors are key players in atherogenesis and -progression 
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Figure 24: Chemokine receptors influence atherogenesis and -progression. Lesion sizes in aortic root sections stained for 
Oil-red O in Apoe-/-Ccr1-/- , Apoe-/-Ccr2-/-, Apoe-/-Ccr5-/- and Apoe-/-Cx3cr1-/- mice. n=10-14, One-way ANOVA with Newman-
Keuls multiple comparison. *Indicates significant differences. 
 
The role of chemokine receptors in atherogenesis, –progression and vascular injury has 
extensively been described.13,20 Employing mouse strains deficient for different chemokine 
receptors, crucial roles in the development of atherosclerosis have been implied for nearly 
all of them. Unfortunately most studies lack a clear differentiation between effects of 
chemokine receptors on leukocyte recruitment and leukocyte homeostasis such as 
mobilization from the bone marrow or apoptosis. Literature reports point towards the 
importance of CCR1/2/5 and CX3CR1 in atherogenesis. In our experiments, mice deficient for 
those chemokine receptors received HFD for 2 months. Lesion sizes in aortic root sections 
stained for Oil-red O were markedly reduced in Apoe-/-Ccr2-/-, Apoe-/-Ccr5-/- and Apoe-/-
Cx3cr1-/-, whereas for Apoe-/-Ccr1-/- only a tendency for reduced lesion sizes could be 
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observed (Figure 24). Of note, after one month of HFD Apoe-/-Ccr1-/- mice display reduced 
lesion sizes (data not shown) whereas an increase in atherosclerotic plaque area has been 
reported for 3 months of HFD.37 
 
3.2.6 Monocytes employ chemokine receptors for arterial recruitment   
In a recent study a tight correlation between lesion sizes and the number of circulating 
monocytes has been described.55 Based thereon we further investigated the relevance of 
different chemokine receptors in monocyte recruitment to sites of atherosclerosis. As the 
Gr1+ monocytes were found to primarily exert pro-atherogenic effects (3.2.3) we focused on 
this subset. Therefore, blood and aortas of mice fed HFD for 2 month were used for flow 
cytometry analysis. Later on those records allowed us to subsequently correlate circulating 
Gr1+ monocyte numbers to the number of Gr1+ monocytes that can be found within the 
aorta/lesion. 
In particular, compared to Apoe-/- mice, the number of Gr1+ monocytes within the aorta was 
significantly decreased in Apoe-/-Ccr1-/-, Apoe-/-Ccr2-/-, Apoe-/-Ccr5-/- but not in Apoe-/-Cx3cr1-/- 
mice (Figure 25A). Neither whole monocyte count nor the number of Gr1+ monocytes in 
blood changed significantly in any receptor deficient mouse strain except for the Apo-/-Ccr2-/- 
mice (Figure 25A). According to literature, in those animals, monocyte counts were 
dramatically decreased.70 Combining those two parameters for every single mouse strain we 
found close correlations in Apoe-/-, Apoe-/-Ccr2-/- and Apoe-/-Cx3cr1-/- mice (Pearson r > 0,9) 
(Figure 25B) whereas correlations for Apoe-/-Ccr1-/- and Apoe-/-Ccr5-/- were completely 
abrogated (Pearson r < 0,5) (Figure 25B). Those findings suggest the importance of CCR1 and 
CCR5 but not CCR2 or CX3CR1 in the recruitment of classical, inflammatory monocytes to 
atherosclerotic lesions. 
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Figure 25: Counts of circulating as well as aortic Gr1+ monocytes directly correlate. A: Assessed Gr1+ monocyte counts 
within aortas (left graph) of mice deficient for ApoE and either CCR1, CCR2, CCR5 or CX3CR1 receiving HFD for 2 months. And 
calculated numbers of circulating whole (middle) as well as Gr1+ monocytes (right). n=8, One-way ANOVA with Newman-
Keuls multiple comparison. *Indicates significant differences. B: Correlation between numbers of Gr1+ monocytes within 
aorta and circulation. Pearson correlation (r) is displayed. 
 
To further elucidate the importance of CCR1 and CCR5 in the arterial recruitment of Gr1+ 
monocytes we used adoptive transfer experiments. Bone marrow derived Gr1+ monocytes 
were isolated using fluorescence activated cell sorting, labeled with CFSE and subsequently 
transferred to Apoe-/- mice fed a HFD for 4 weeks. Quantification of CFSE+ cells that could be 
found in the aorta 24h after transfer to Apoe-/- mice corroborated the significance of CCR1 
and CCR5 in the recruitment of Gr1+ monocytes to large arteries. Monocytes deficient for 
those chemokine receptors displayed impaired recruitment compared to that from control 
Apoe-/-. Again, deficiency for either CCR2 or CX3CR1 did not influence the recruitment of 
Gr1+ monocytes implying an exclusive role of CCR2 in monocyte homeostasis but not 
recruitment to sites of atherosclerosis (Figure 26). 
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Figure 26: Adoptive transfer of bone marrow derived Gr1+ monocytes to Apoe-/- mice. CFSE labeled 1x106 bone marrow 
derived Gr1+ monocytes were adoptively transfered to Apoe-/- mice that had received a HFD for 4 weeks. After 24h aortas 
were harvested, enzymatically digested and further investigated by flow cytometry. CFSE+ cells could be detected in aortas 
(representative dot plots) and aortic root sections (middle panel). CFSE+ Gr1+ monocytes in lysates from aortas were 
quantified (right graph). n=7, Kruskal-Wallis test with posthoc Dunn test. *Indicates significant differences to control (grey). 
 
3.3 Neutrophil/Monocyte interaction in atherogenesis 
3.3.1 Neutrophils pave the way for monocytes in atherogenesis 
In acute inflammatory responses it has been demonstrated that neutrophil secretion 
products pave the way for Gr1+ monocytes.159 Beside their effects on monocytes, neutrophils 
have been implicated in recruitment of macrophages, dendritic cells and lymphocytes160, all 
of which play important roles in atherogenesis and –progression.6,148 To address the 
question whether similar mechanisms could be observed in a chronic inflammation model 
such as atherosclerosis we specifically depleted neutrophils and assessed the cellular 
composition of enzymatically digested aortas. Neutropenic mice as well as mice with normal 
white blood cell count received one month of HFD. Depletion of neutrophils reduced the 
amount of CD45+ cells in aortic lysates, much of which was attributed to reduced neutrophil 
counts (Figure 27). In addition, the prevalence of CD45+CD115+Gr1+CD11bhi inflammatory 
monocytes and CD45+F4/80+Gr1-CD11blo macrophages was significantly reduced. 
Furthermore, neutropenic mice exhibited a higher relative content of CD3+ T lymphocytes. In 
contrast, aortic counts of dendritic cells and resident Gr1- monocytes were not affected.  
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Figure 27: Neutrophils pave the way for recruitment of inflammatory leukocyte subsets in early atherosclerosis. 
Composition of enzymatically digested aortas of Apoe-/- mice after one month of HFD being either neutropenic or exhibiting  
intact white blood count. Bar graphs display aortic leukocyte (CD45+) and neutrophil (CD45+CD11b+Gr1+F4/80-CD115-) 
counts. Pie charts display the distribution of leukocyte subsets in enzymatically-digested aortas of mice with intact WBC and 
neutropenia whereby the number of neutrophils subtracted from the total CD45+ cell count was set to 100% for each 
mouse. Leukocyte populations with significant differences between the treatments are coloured and further exemplified in 
representative dot blots. n=6. Mann-Whitney. 
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4.1 Neutrophils initiate early atherosclerosis development 
4.1.1 Hypercholesterolemia alters neutrophil homeostasis 
Hyperlipidemia exhibits apparent effects on homeostasis of bone marrow-derived cells, with 
increases in circulating numbers of lymphocytes, platelets, monocytes, and progenitor 
cells.96,148,149 Although hyperlipidemia-induced perturbations in leukocyte homeostasis are 
widely unclear, in a recent study expansion of inflammatory monocytes could be positively 
correlated with serum cholesterol levels.96 However, such investigations do not exist for 
other myeloid cell subsets such as neutrophils. This work provides evidence that 
hypercholesterolemia induces neutrophilia via multifaceted mechanisms. 
Neutrophil homeostasis is regulated at various levels including production, mobilization, and 
clearance much of which is regulated by an equilibrium of chemokines, cytokines, and 
growth factors. Our study shows that hypercholesterolemia induces G-CSF, the key cytokine 
in regulating granulopoiesis. G-CSF itself is primarily induced by increased levels of TNF and 
IL-17, the latter of which is the effector of a neutrophil clearance feed-back loop.113 Our 
study, but also recent findings by others,161 evidenced increased TNF and IL-17 levels in the 
plasma of atherosclerotic mice. The cellular origin of these mediators remains so far elusive. 
G-CSF not just stimulates proliferation of myeloid precursors, but also suppresses bone 
marrow CXCL12 (SDF1α) production, thereby reducing clearance of aged neutrophils.99,112 
Finally, hypercholesterolemia enhances serum CXCL1 levels, which promotes neutrophil 
mobilization via CXCR2. Hence, hyperlipidemia imbalances the tightly regulated cytokine 
system controlling neutrophil homeostasis at various levels ultimately increasing peripheral 
neutrophil counts (Figure 28). Macrophage migration inhibitory factor (MIF) has recently 
identified as a non-cognate ligand for CXCR2 and CXCR4.162 Intravenous injection of 
recombinant MIF (rMIF) into wt mice efficiently mobilized neutrophils from bone marrow 
(data not shown) suggesting the involvement of MIF in inflammatory neutrophilia. Indeed, 
for an acute model of ovalbumin-induced airway inflammation elevated levels of MIF within 
the bronchoalveolar lavage (BAL) were detected which was further accompanied by an 
increased neutrophil count. In line, blocking MIF with an antibody significantly reduced 
neutrophil numbers.163 Although, MIF serum levels have not been tested in the here 
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presented thesis, a more recent clinical study demonstrated that serum concentrations of 
MIF are not associated with the risk for coronary heart disease.164 Assuming a positive 
correlation between neutrophil count and development of atherosclerotic lesions (Figure 6), 
it might imply a dispensable role of MIF in neutrophil homeostasis under steady state as well 
as in chronic inflammation which potentially differs under acute inflammatory conditions. 
 
4.1.2 Neutrophils fuel atherosclerosis during early stages 
Neutrophils represent a so far underappreciated leukocyte subset in the pathophysiology of 
atherosclerosis. This is mainly due to the fact, that these cells have rarely been detected 
within atherosclerotic lesions. Traditionally, neutrophils are looked upon as short-lived cells 
that are recruited early in inflammatory responses.127 Within hours after tissue damage, 
neutrophils are mobilized from the bone marrow resulting in an acute neutrophilia.98 
Involvement of neutrophils in atherosclerosis, especially during onset appears logic, since its 
pathophysiology is characterized by endothelial dysfunction during the first stage a 
circumstance characterized by upregulation of e.g. ICAM-1 which typically mediates 
neutrophil adhesion. Once neutrophils emigrated to the injured tissue they sequentially 
release preformed granule proteins that subsequently attract inflammatory monocytes.165 In 
contrast to monocytes and their descendants which are long-lived and hence easily 
detectable in atherosclerotic lesions, neutrophils undergo apoptosis shortly after they have 
emigrated. Thus it is not surprising that these cells cannot be detected in high numbers in 
atherosclerotic plaques. Neutrophil extravasation involves the coordinated and well-
regulated interaction of selectins, cell adhesion molecules and chemokines. It has previously 
been reported that the majority of transient leukocyte endothelial contacts in 
atherosclerosis is attributable to neutrophils, which interact with endothelial selectins.166,167 
Here we extend these observations, describing that neutrophils adhere to the lumen of large 
arteries at early stages of atherosclerosis. The importance of molecules, such as P-selectin, 
β2-integrins, and ICAM-1 in neutrophil adhesion and recruitment is without doubt. Hence, 
the vast reduction of atherosclerotic lesions in mice lacking P-selectin17, the common β2-
integrin chain CD18,25 or its counter receptor ICAM-118 may at least in part be attributed to 
reduced neutrophil extravasation. In addition, leukotriene B4 is a potent chemoattractant 
for neutrophils and deletion of its high affinity receptor BLT1 reduces atheroslerosis 
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specifically at early stages of atherosclerosis.168 In light of the data presented here, this 
stage-specific effect may be attributed to the importance of neutrophils in initial phases of 
atherosclerotic lesion formation. 
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Figure 28: Hypothesized mechanisms underlying HFD-induced neutrophilia and neutrophil recruitment. High cholesterol 
levels induce TNFα and IL17, thereby increasing G-CSF synthesis. Higher G-CSF level suppresses CXCL12 (SDF1α) release 
from osteoblasts hence lowering retention of fresh and clearance of senescent CXCR4high neutrophils. Mobilization of 
neutrophils is further increased by elevated serum CXCL1 and higher surface expression of CXCR2. Recruitment of 
neutrophils to sites of atherosclerosis is mediated by the chemokine receptors CCR1, CCR2, CCR5 and CXCR2. Emigration via 
CCR1 and CCR5 is dependent on platelet derived CCL5. Once emigrated, neutrophils secrete a variety of preformed granule 
proteins. Thereby recruitment of inflammatory monocytes is triggered which is hypothesized to be aggravated the more 
neutrophils are present at sites of atherosclerosis. New findings achieved by this study are highlighted in red. 
 
Besides the presence of neutrophils in atherosclerotic lesions which has already been 
described for monkey124 and mouse47 increased neutrophil counts have been associated to 
incidence of myocardial infarction.125,126 In line with those clinical studies increased 
neutrophil counts caused by disrupting CXCR4-CXCL12 axis by a small-molecule antagonist 
aggravated atherosclerosis.47 Similar results were observed employing mice deficient for the 
transcription factor IRF8 leading to severe neutrophilia. (Döring et al., unpublished). The 
study presented here gives direct evidence for a positive correlation between peripheral 
neutrophil counts and lesion sizes within the aortic root after 4 weeks of HFD. Additionally, it 
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could be demonstrated that neutrophils infiltrate atherosclerotic vessels primarily during 
early stages and in line with this depletion of neutrophils reduces atherosclerotic lesion 
burden only in the initial phase. Neutrophils may exert pro-atherogenic effects via several 
direct and paracrine mechanisms. Neutrophils produce large amounts of oxygen radicals via 
NADPH oxidase and myeloperoxidase (MPO). Much of the oxygen radicals are secreted 
extracellularly, where they have been proposed to be key mediators involved in the 
oxidation of LDL particles by which LDL is entrapped in the subendothelial space. Of note, 
reactive oxygen species (ROS) can directly induce apoptosis of cells thereby promoting 
inflammation. Emigrating neutrophils release a wide panoply of granule proteins which act 
as extracellular regulators of inflammatory processes.169 MPO for example is released from 
neutrophil primary granules once the neutrophil has emigrated. Its transcytosis across 
endothelium allows for interaction with leukocytes in flow and modification of leukocyte 
adhesion.170 Furthermore, MPO acts as a leukocyte-derived NO oxidase, which limits NO 
bioavailability thus promoting impairment of endothelial cell function.171 In patients with 
stable coronary artery disease, plasma MPO levels have been shown to predict the 
prevalence and extent of coronary disease and future risk of cardiovascular events.172 Other 
granule proteins may serve as link between the early efflux of neutrophils and the 
recruitment of inflammatory monocytes. In this context, LL-37 and azurocidin have recently 
gained attention, as they specifically induce recruitment of inflammatory monocytes via 
involvement of formyl-peptide receptors.159,160 Accordingly, we here show that digested 
aortas of neutropenic mice contain lower numbers of inflammatory monocytes and 
macrophages, which likely are descendants. 
 
4.1.3 Chemokine receptors trigger arterial recruitment of neutrophils 
Chemokine receptors and their ligands are major trigger units in activation of leukocytes 
thereby promoting their arrest and (trans-)migration to sites of inflammation. One aim of 
this study was to investigate the importance of specific chemokine receptors in arterial 
neutrophil recruitment. Deletion of chemokine receptors CCR2 and CXCR2 results in reduced 
atherosclerotic burden.20 Given the importance of both these receptors in transmitting 
chemotactic signals for neutrophils, the atherosclerotic phenotype in these mice may in part 
be attributed to diminished arterial neutrophil infiltration. The number of aortic neutrophils 
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in a CXCR2 knockout-model was significantly reduced. Besides CXCL8 as a cognate ligand, as 
already mentioned in a previous section MIF may play an important role in arterial 
recruitment of neutrophils. Its expression is upregulated in endothelial cells, smooth muscle 
cells and macrophages during the development of atherosclerotic lesions in humans, rabbits 
and mice.173-175 Chemotactic effects of MIF on neutrophils have been demonstrated to 
follow a typical bell-shaped dose-response curve and MIF-dependent neutrophil 
transmigration could be blocked in vitro using an antibody against CXCR2.162 Atherosclerotic 
mice deficient of MIF displayed reduced lesion formation already after 12 weeks of HFD176 
indicating a role of MIF not only in later162,173 but also in early atherosclerosis which might be 
partially attributable to MIF-dependent arterial neutrophil recruitment. 
Our data also describe an important role of CCR1 and CCR5 in adhesion and extravasation of 
neutrophils to large arteries. It has previously been shown that the utilization of monocytic 
CCR1 and CCR5 in arterial recruitment is partially due to chemokines that are deposited by 
activated platelets.21,22 This mechanism is primarily important in early stages of 
atherosclerosis177 and hence led us to investigate the importance of platelet-derived 
chemokines in neutrophil adhesion and recruitment. Indeed, we found that CCL5 deposited 
by activated platelets induces neutrophil adhesion through engagement of CCR1 and CCR5. 
The contribution of CCR1 and CCR5 to the extent of lesion formation may differ, as a 
prevailing role of CCR5 in atherosclerosis has been reported.37 CXCR4 on the other hand, 
seems to have a mere homeostatic effect as has previously been demonstrated.47 
 
4.1.4 Perspective – Neutrophils 
In the here presented work, the important role of neutrophils during onset of 
atherosclerosis was established for the first time. However, unlike monocytes, macrophages 
and lymphocytes, neutrophils are only a small cell population in atherosclerotic plaques. 
Hence, neutrophils have to be regarded as promoters of the complex pathophysiology 
underlying atherosclerotic lesion formation. Much of the proinflammatory activity of 
neutrophils is based on the secretion of preformed granule proteins thereby triggering influx 
of inflammatory monocytes as described for general onset of inflammation.165 Thus, future 
studies may concentrate on neutrophil secretion products as cathepsin G, LL37 (Cramp in 
mouse) or azurocidin and their influence on development of atherosclerosis. With regard to 
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the fact that those three secretion products involve activation of formyl-peptide receptors 
(FPRs), a family of evolutionarily conserved heptahelical G-protein-coupled receptors165 this 
might also be a follow-up study of high interest. Regarding the new insights into 
deregulation of neutrophil homeostasis under hyperlipidemic conditions future studies may 
aim to interfere or manipulate those mechanisms at different points thereby lowering 
neutrophil numbers to basal levels. Finally, the finding from this study that neutrophils 
employ different chemokine receptors to enter micro- and macrovascular beds may open 
new strategies for future investigations and therapeutic approaches. 
 
4.2 Inflammatory Gr1+ monocytes dominate atheroprogression 
4.2.1 New insights into HFD-induced Gr1+ monocytosis 
Hyperlipidemia-induced Gr1+ monocytosis has previously been described as a crucial step in 
development of atherosclerosis.96 Thus, elevated levels of serum cholesterol correlated with 
monocytosis resulting from continued bone marrow production of inflammatory monocytes, 
increased survival of these cells in the periphery, and impaired conversion to resident 
monocytes.50,96 In line, treatment with serum cholesterol lowering statins could significantly 
reduce peripheral Gr1+ counts.96 However, a conclusive mechanistic link between 
hypercholesterolemia and monocytosis remains unclear. Because LDL can induce aortic 
endothelial cells to synthesize and secrete M-CSF,178 a growth factor known to primarily 
drive monocyte development,73-75 we assessed whether this factor is altered in mice 
receiving HFD. In this study elevated serum concentrations of M-CSF were detected under 
HFD, which may in part be responsible for continued Gr1+ proliferation in bone marrow. A so 
far unknown expression pattern of CXCR2 between Gr1+ and Gr1- monocytes might also 
enlighten new mechanistic insights. CXCR2 is higher expressed on inflammatory monocytes 
and further increases under HFD. Interestingly, neither MCP-1 nor MCP-3, both of which 
regulate Gr1+ monocyte efflux from bone marrow under steady state as well as acute 
inflammatory conditions,70,84 were increased under hypercholesterolemia. Suggesting a 
more prominent role of CXCR2 CXCL1 axis in HFD induced Gr1+ monocytosis, intravenous 
injection of rCXCL1 increased peripheral counts of inflammatory monocyte due to 
mobilization from bone marrow as well as the splenic reservoir. In line, treatment with an 
antibody against CXCL1 which has been shown to be increased under hyperlipidemic 
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conditions abolished HFD-induced monocytosis in mice. The differential expression of CXCR2 
between both monocyte subsets might therefore explain why peripheral numbers of Gr1+ 
but not Gr1- low monocytes are elevated under HFD. Of note, in a recent study aiming at the 
role of MIF in atheroprogression, treatment of mice with already developed atherosclerotic 
lesions with an anti-CXCL1 antibody could slightly decrease further plaque development. 
However, the difference for anti-CXCL1 treatment compared to control was not significant; 
blockade of MIF resulted in a striking lesion reduction.162 Furthermore, a study from 1982 
showed a correlation between monocyte counts and serum concentration of MIF.179 Taken 
together, this study is the first to highlight the CXCR2-CXCL1 axis being important in HFD-
induced monocytosis (Figure 29).  
 
4.2.2 Gr1+ monocytes dominate atheroprogression 
Monocytes are supposed to accumulate continuously during atheroma formation, lesion 
sizes increase in proportion to monocyte accumulation, and recruitment is augmented with 
hypercholesterolemia.180 However, specific roles of both monocyte subsets in atherogenesis 
still remain elusive. Although heterogeneity of monocytes has extensively been described 
and numerous studies aimed at dissecting the role of either subset, especially for the Gr1- 
subset defined functions remain largely unknown.60,181 This is mainly due to technical 
problems. Compared to neutrophils, specific depletion of either monocyte subset to 
investigate its specific role is so far not possible therefore being one of the key challenges. In 
this study an experimental setup was designed employing the cytostatic drug 
cyclophosphamide to completely block endogenous leukocyte proliferation and renewal. 
Mice, fed HFD for 4 weeks were injected two times a week for additional 4 weeks. By 
substituting whole WBC, or whole WBC lacking either Gr1+ or Gr1- monocytes we aimed at 
elucidating the specific roles of either monocyte subset in atheroprogression. Indeed, mice 
treated with cyclophosphamide displayed significantly reduced lesion formation. Of note, 
substitution of WBC from atherosclerotic donor mice exhibited lesion sizes that did not differ 
from mice not receiving cyclophosphamide, clearly indicating functionality of the 
experimental setup and additionally confirming a study that positively correlated peripheral 
monocyte counts with lesion formation.55 
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Figure 29: Hypothesized mechanisms underlying HFD-induced Gr1+ monocytosis and recruitment. High cholesterol 
induces production and secretion of M-CSF by aortic endothelial cells leading to increased monocyte proliferation. 
Mobilization of Gr1
+
 monocytes from bone marrow as well as the splenic reservoir is partially dependent on high CXCR2 
expression and HFD-induced, increased CXCL1 serum levels. Circulating inflammatory monocytes can be recruited to sites of 
atherosclerosis employing the chemokine receptors CCR1, CCR5 and most likely CXCR2. However, CCR2 is not involved in 
arterial recruitment rather than in regulating monocyte homeostasis. 
 
Substitution of whole WBC either lacking Gr1+ or Gr1- monocyte subset provided clear 
evidence for the indispensible role of Gr1+ monocytes in plaque development whereas lesion 
sizes were not altered in mice lacking Gr1- monoctyes. Monocyte/macrophage accumulation 
within atherosclerotic lesions however followed the same tendencies as evidenced by Mac2 
stainings. Hence, this study clearly highlights the relevance of Gr1+ monocytes to be one 
driving force in atherogenesis and -progression. In a convincing study investigating the role 
of either monocyte subset in a model of acute myocardial infarction the authors elegantly 
showed that both subsets are involved during different stages and, resulting from that 
concluded different functions.158 While Gr1+ monocytes primarily dominated the early phase 
directly after myocardial infarction, Gr1- monocytes infiltrate infarcted tissue during later 
phases. Depletion of whole monocytes during early stages resulted in increased areas of 
debris and necrotic tissues indicating Gr1+ monocytes to be responsible for proteolysis, 
inflammation, and phagocytosis. In contrast, lack of monocytes during later stage implied 
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relevance of Gr1- monocytes in accumulation of myofibroblasts, angiogenesis, and 
deposition of collagen.158 To test whether similar functional machineries might be true in 
development of atherosclerosis, content of necrotic cells as well as collagen content was 
assessed. However, alterations of necrotic cell counts between control animals and 
leukopenic mice were not significant the latter displayed a clear tendency to higher TUNEL+ 
cell numbers. This might partially be attributable to the overall decrease of immune cells due 
to leukopenia. Substitution of WBC lacking Gr1+ monocytes led to clearly increased numbers 
of necrotic cells suggesting the relevance of Gr1+ monocytes in clearance of necrotic cells as 
observed for myocardial infarction. In contrast, lack of Gr1- monocytes did not affect 
necrotic cell clearance. Assessing collagen content by Sirius red staining did not give any 
indication. However, deposition of collagen is a characteristic of advanced, already 
developed atherosclerotic plaque. Thus, 8 weeks of HFD in total might be too short for 
conclusive results.  
Once a monocyte has entered the atherosclerotic plaque it will differentiate to a 
macrophage. Macrophages are known as cells with high plasticity characterized by 
phenotypical and functional adaptions depending on environmental stimuli.182,183 M1 
macrophages, also named classically activated macrophages, exhibit inflammatory 
properties and require inflammatory stimuli such as LPS or IFN-γ. In contrast, M2 
macrophages, or alternatively activated macrophages exert regulatory functions and evolve 
after stimulation with IL-4 and IL-13.181 Whereas M1 polarization is characterized by 
expression of TNFα, alternatively activated M2 macrophages are reported to secrete Il-10.183 
Both cytokines should be detected in sera of mice substituted with WBC either lacking Gr1+ 
or Gr1- to assess whether the one or the other monocyte subset reinforces a specific 
macrophage phenotype. However, levels of both cytokines were below detection limit (data 
not shown). Thus, it still remains unclear whether monocyte subsets can exclusively give rise 
to a specific type of macrophages. To further address this question aortic root sections will 
be stained for arginase I (ArgI) and arginase II (ArgII) (in progress), markers reported to be 
specific for either M2 or M1 polarization in development of atherosclerosis.184 However, 
ArgI+ (M2) macrophages were shown to infiltrate early atherosclerotic lesions whereas ArgII+ 
(M1) cells appeared in lesions of aged atherosclerotic mice184 it remains unclear what 
indications we will obtain from mice fed HFD for only 8 weeks. 
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4.2.3 Chemokine receptors differentially affect Gr1+ monocytes at various levels 
Monocyte counts positively correlate with atherosclerotic lesion sizes.55 In addition, HFD-
induced monocytosis is solely caused by expansion of Gr1+ monocytes.96 Together with 
results obtained in this study, Gr1+ rather than Gr1- monocytes must be look upon as 
primary driving force in atheroprogression. A crucial step in leukocyte recruitment is 
chemokine-dependent activation, mediating adhesion and (trans-) migration of immune 
cells. Targeting interaction of chemokines and their receptors has recently been described to 
be a useful therapeutic tool in atherosclerosis33 thus specific blockade of those receptors 
might be an elegant way to prevent subsequent recruitment of Gr1+ monocytes. For that 
reason, detailed understanding of which chemokine receptors are employed by 
inflammatory monocytes to enter atherosclerotic lesions is essential. So far CCR2 is 
supposed to mediate monocyte recruitment. Atherosclerotic mice deficient of CCR2 display 
reduced lesion size and monocyte/macrophage content, implying involvement of this 
receptor in monocyte recruitment.34 However, mice deficient of CCR2 display markedly 
reduced peripheral Gr1+ monocyte counts.70 The study presented here aimed at discerning 
homeostatic and recruitment functions of individual chemokine receptors. To this end we 
employed three independent approaches to dissect chemokine receptor-mediated 
recruitment independent of monocyte mobilization from the bone marrow. In a first step, 
lesion formation was assessed in mice deficient for the receptors CCR1, CCR2, CCR5 and 
CX3CR1 all of which have been reported to affect atherosclerosis.20 Besides this more 
descriptive readout, counts of aortic Gr1+ monocytes as well as the number of peripheral 
inflammatory monocytes were taken into account. Correlation of these two parameters 
clearly verified significance of CCR1 and CCR5 but not CCR2 or CX3CR1 in arterial recruitment 
of Gr1+ monocytes (Figure 29). This was further corroborated by adoptive transfer 
experiments. 
In this study, no significant changes in formation of atherosclerotic lesions in mice deficient 
of CCR1 was observed after 8 weeks of HFD which is in line with a recent study.38 Of note, 
mice lacking CCR1 that received HFD for 4 weeks displayed reduced atherosclerotic lesions 
compared to control (data not shown). In contrast, atherosclerosis is aggravated in CCR1 
deficient animals fed a HFD for a minimum of 3 months.37,38 However, data from this study 
clearly suggest an important role of CCR1 in arterial recruitment of inflammatory monocytes. 
That ultimately leads to the question why there is no reduction in plaque formation, 
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especially if continuous monocyte influx is supposed to be one of the driving forces in 
atherogenesis and –progression. Braunersreuther et al. described increased numbers of 
CD3+ T cells within atherosclerotic plaques of mice deficient for CCR1 and especially the 
imbalance between Th1 and Th2 with CCR1 deletion favouring a proatherogenic Th1-type 
response. This was further accompanied by higher expression of IFNγ, a proinflammatory 
cytokine indicating Th1-type response, within the plaque.37 Although mechanisms underlying 
enhanced T cell infiltration and shift to proinflammatory Th1-type response in mice bearing 
deficiency in CCR1 can only be hypothesized, a negative systemic net effect overlying 
diminished arterial recruitment of monocytes and neutrophils can be concluded. However, 
deficiency in CCR5 widely protected from lesion formation which is quiet surprising as both 
receptors exhibit several similar ligands such as RANTES (CCL5). Lack in CCR5 has been 
reported to result in a more anti-inflammatory surrounding characterized by increased IL-10 
and decreased levels of IFNγ.37 Since SMC are a main source of anti-inflammatory IL-10 and 
mice which have been transplanted with Ccr5-/- bone marrow display only mildly reduced 
lesion sizes40 it is most likely that a part of the effect is attributable to CCR5 deficiency in 
atherosclerosis relies on non-hematopoietic CCR5+ SMC recruited to the lesion.37,185 Besides 
the role of CCR5+ SMC, Potteaux et al. demonstrated bone marrow derived CCR5 to be 
important for continuous recruitment of monocytes as macrophage content was already 
decreased around 30% after 8 weeks of HFD although lesion sizes did not differ compared to 
control.40 Together with the findings from this study it further points the importance of CCR5 
in recruitment of inflammatory monocytes to atherosclerotic lesions to subsequently 
replenish macrophage content. Further support stems from a study by Tacke et al. in which 
latex bead labelled monocytes displayed reduced efficiency to enter atherosclerotic lesions 
after applying an antiCCR5 antibody.89 Additionally, the authors observed differential 
expression of CCR5 between Gr1+ and Gr1- monocytes of which the latter was reported to 
express higher levels. However, such differences cannot be supported by this work. The 
same study used a transplantation model of aortic arches with already developed 
atherosclerotic lesions to mice deficient in either CX3CR1 or CCR2 to elucidate the role of 
these receptors in recruitment of inflammatory monocytes. Numbers of Gr1+ monocytes 
were decreased due to the lack of the respective receptor.89 These results contrast to the 
role of both receptors demonstrated here stating CCR2 as well as CX3CR1 to be dispensable 
in Gr1+ recruitment. That might be partially attributable to the model chosen and the latex 
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bead labelling methodology. It seems to be more likely that both receptors, CCR2 and 
CX3CR1 influence Gr1+ homeostasis at different stages. CX3CR1 was recently described as a 
survival signal and lack of that receptor led to premature apoptosis. Conversely stimulating 
cells with the ligand Fraktalkine (CX3CL1) rescued cells from induced cell death.50 That might 
in part explain the protective effect in atherogenesis as well as decreased numbers of 
monocytes and macrophages within atherosclerotic lesions as once those cells are 
emigrated, they may undergo early apoptosis. CCR2, however primarily determines Gr1+ 
monocyte egress from bone marrow. Deficiency in this receptor results in markedly reduced 
peripheral monocyte counts and did not affect recruitment capacity of Gr1+ monocytes to 
sites of atherosclerosis. This finding is in line with a study demonstrating that CCR2-/- 
monocytes could traffic to sites of infection, demonstrating that CCR2 is not required for 
migration from circulation into tissues.70 Further support stems from a study by Huo et al. 
from 2001 describing monocytic arrest under ex vivo perfusion conditions to be dependent 
on CXCL1, but not MCP-1.186 However, the authors proof CXCR2-dependent monocyte 
recruitment under atherogenic conditions. Although, recruitment of Gr1+ monocytes via the 
chemokine receptor CXCR2 was not part of this work we could demonstrate a higher 
expression of CXCR2 on inflammatory compared to nonclassical, resident monocytes. Thus, a 
CXCR2/CXCL1 axis, eventually involving different ligands such as MIF,162 might additionally 
explain different recruitment behaviour between both monocyte subsets. 
 
4.2.4 Perspectives – Monocytes 
This study unveiled the inflammatory monocyte subset to be the driving force in 
atheroprogression. However, the role of resident Gr1- still remains elusive. Future studies 
should primarily focus on this monocyte subset. Therefore, new experimental setups need to 
be developed to investigate the significance of those cells. As their involvement in 
atheroprogression was neglected in this work, a role during initial stages of plaque formation 
or during plaque destabilization remains conceivable. Resident monocytes were reported to 
patrol healthy vessel walls to somehow alarm the immune system in case of emergency.97 As 
this mechanism was only shown in veins rather than large arteries it has to be clarified if 
similar processes occur in atherosclerosis. Improvements of techniques to differentially label 
both monocyte subsets to trace them in vivo are required to further elucidate functions of 
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Gr1- monocytes. The work presented here clearly dissects the relevance of different 
chemokine receptors for Gr1+ monocytes to enter atherosclerotic lesions. CCR2 and CX3CR1 
could clearly be demonstrated not to affect recruitment behaviour rather than monocyte 
homeostasis. In contrast CCR1 and CCR5 are needed to get to sites of atherosclerosis. 
However, those two receptors widely affect other leukocytes such as T cells it would be of 
high interest to unveil involved ligands and how they differentially influence Gr1+ monocyte 
recruitment. The finding of CXCR2 and its ligand CXCL1 to be involved in Gr1+ monocyte 
homeostasis under HFD as well as recruitment offers new insights for future therapies and 
should be investigated more detailed. 
 
4.3 Neutrophils and monocytes – ill alliance in atherogenesis 
 
Partnership of neutrophils and monocytes in onset and resolution of inflammation is widely 
accepted.165 However the multi-step machinery characterized by neutrophil egress initiated 
by tissue resident cells (e.g. macrophages or patrolling resident monocytes) followed by 
neutrophil influx and recruitment of inflammatory monocytes by neutrophil secretion 
products and finally resolution of inflammation through signals of phagocytes, were so far 
only proven under acute inflammatory conditions.165 The work presented here is the first 
demonstrating that similar mechanisms hold true in atherogenesis clearly confirming an ill 
alliance of this two myeloid cell subsets in initiation and development of atherosclerosis. 
Mice depleted of neutrophils exhibited not only significantly reduced arterial neutrophil 
counts but also diminished numbers of inflammatory monocytes and as a consequence, 
macrophages. These results clearly suggest a chain reaction starting with neutrophil 
recruitment followed by monocyte infiltration and macrophage accumulation within 
atherosclerotic lesions. However, the mechanisms underlying neutrophil-induced monocyte 
recruitment were not illuminated by this work, involvement of neutrophil granula proteins in 
arterial monocyte recruitment is most likely and should be addressed in future studies. As 
neutrophil recruitment partially based on platelet-derived CCL5 it is still unclear whether 
monocyte recruitment occurs via the same mechanism or if it more depends on neutrophil-
derived factors. 
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Of note, peripheral neutrophil as well as Gr1+ monocyte counts were markedly increased 
under HFD maybe indicating a general mechanism underlying HFD-induced, elevated 
myeloproliferation. Interestingly the recently described pool of inflammatory monocytes in 
spleen is reported to increase by time under HFD96 raising the question whether a similar 
mechanism might be true in neutrophil homeostasis. However, by feeding HFD for up to four 
weeks, no change could be observed by indirect measurement of MPO activity in lungs 
described to be a pool of marginated neutrophils. To this point, the impact of CXCR2 and its 
ligands might be more critical than taken into account. Hence, increased CXCL1 levels under 
HFD not only led to neutrophilia and Gr1+ monocytosis but also affected neutrophil as well 
as monocyte recruitment. So far, one could only speculate whether signalling via CXCR2 and 
its ligands such as CXCL1, IL8 or MIF have a direct effect on increased myeloid cell counts. 
For instance MIF was demonstrated to sustain macrophage survival and function by 
suppressing activation induced p53-dependent apoptosis.187 However, future studies should 
address the question whether HFD induced myeloproliferation is partially dependent on 
CXCR2 signalling. 
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Atherosclerosis is currently viewed as a chronic inflammatory disease of the arterial vessel 
wall with prominent roles for endothelial cells, T lymphocytes and monocyte-derived 
cells.6,57 Hypercholesterolemia is a major risk factor activating these cell types resulting in 
enhanced expression of cell adhesion molecules, chemokines, and pro-inflammatory 
cytokines ultimately promoting arterial infiltration with immune cells.148 
Monocytes/macrophages are traditionally seen as main actors in development and 
progression of atherosclerosis. However, relevance of the two principal monocyte subsets 
has so far not taken into account. Although a recent study deals with expansion of 
inflammatory monocytes under hyperlipidemia96 detailed mechanisms as well as the 
importance of either monocyte subset itself still remains elusive. 
Neutrophils are a so far underappreciated leukocyte subset in atherosclerosis. Recent work 
suggests a prominent role for these cells and this study is the first to link early stages of 
atherosclerosis to hypercholesterolemia-induced neutrophilia which can be attributed to 
stimulation of granulopoiesis, enhanced bone marrow mobilization as well as reduced 
peripheral clearance. Increased peripheral neutrophil counts were found to closely correlate 
with the extent of early atherosclerosis formation. In these initial stages, neutrophils 
prominently infiltrate arteries through the involvement of CCR1, CCR2, CCR5, and CXCR2. 
The utilization of CCR1 and CCR5 contrasts to peripheral neutrophil recruitment and may be 
ascribed to endothelial deposition of CCL5 by platelets. Once emigrated, neutrophils 
promote atherogenesis as evidenced by reduced plaque sizes in neutropenic mice. Thus, the 
employment of CCR1 and CCR5 in arterial but not venous recruitment may emerge as a 
feasible option for therapeutic targeting. Clearly, the addition of the neutrophil as a 
previously not fully appreciated player in atherosclerosis increases the complexity of cellular 
interactions in disease pathogenesis, but also harbours valuable strategies for prevention 
and treatment. 
In the second part of this work the importance of either monocyte subset was dissected. 
Besides increases in M-CSF-driven production of Gr1+ monocytes a new link between 
augmented CXCL1 levels and CXCR2 expressed by inflammatory monocytes provide insights 
to mechanisms underlying HFD-induced monocytosis. Inflammatory monocytes were clearly 
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shown to be key players in atheroprogression rather than Gr1- monocytes. Contrasting 
previous studies only CCR1 and CCR5 were crucial for Gr1+ moncytes to enter atherosclerotic 
arteries. However, neither CCR2 nor CX3CR1 were essential in monocyte recruitment as 
deficiency of those receptors did not uncouple the tight correlation between peripheral Gr1+ 
monocyte counts and arterial monocyte numbers. These results were further corroborated 
by an adoptive transfer experiment implying a more essential role of CCR2 and CX3CR1 in 
monocyte homeostasis and life cycle. 
In conclusion, the here presented work illustrates a partnership of neutrophils and 
monocytes in onset and development of atherosclerosis which can be characterized to be an 
ill-alliance. However, underlying mechanism concerning neutrophil-induced monocyte 
recruitment remains elusive and future studies shedding light on these interactions are 
needed. 
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Atherosklerose ist ein chronisch-entzündlicher Prozess der arteriellen Gefäßwand, der in 
einem stadienhaften Verlauf zunächst zur Stenosierung der Arterie und später durch Ruptur 
der atherosklerotischen Läsion mit nachfolgender Thrombosierung zu Herzinfarkt und 
Schlaganfall führt.1,2. Während der letzten Jahrzehnte konnte bewiesen werden, dass 
maßgeblich low-density-lipoprotein (LDL) und dessen oxidierte Form (oxLDL) eine 
Entzündung des Endothels bewirken.188,189 Nach Initiation der Entzündung produzieren 
Endothelzellen, glatte Muskelzellen und Gewebsmakrophagen, Chemokine, welche 
wiederum die Rekrutierung und transendotheliale Migration von Immunzellen, wie 
beispielsweise Monozyten oder T-Lymphozyten, bewirken. Die Rolle von Phagozyten in der 
Pathophysiologie der Atherosklerose, also vorrangig Monozyten und Makrophagen, unterlag 
in den letzten Jahrzehnten weitreichenden Untersuchungen.6 Monozyten werden nach 
neueren Erkenntnissen in zwei Untergruppen unterteilt. Zum einen die klassischen, auch 
inflammatorische Monozyten genannt. Zum anderen die nicht-klassischen oder auch 
residenten Monozyten.72 Obwohl eine Studie aus den letzten Jahren erhöhte Zahlen 
inflammatorischer Monozyten in Mäusen mit gesteigerten Blutfettwerten nach fettreicher 
Diät nachweisen konnte und beide Parameter signifikant korrelierten,96 ist die genaue 
Beteiligung beider Untergruppen von Monozyten in der Entwicklung der Atherosklerose 
weitestgehend unverstanden und bisher nicht näher untersucht worden. Zu den 
phagozytierenden Zellen gehören auch die Neutrophilen Granulozyten. Deren Beteiligung an 
der Atherogenese wurde bisher unterbewertet, da diese Zellen, wenn überhaupt, nur in 
geringer Zahl in atherosklerotischen Läsionen nachgewiesen werden konnten. Eine größere 
Bedeutung dieser Zellen wurde aber in jüngeren Publikationen impliziert.161  
In der vorliegenden Arbeit konnte gezeigt werden, dass fettreiche Diät in Apolipoprotein E 
(Apoe) defizienten Mäusen zu einer Leukozytose führt, welche unter anderem auf eine 
Neutrophilie zurückzuführen ist, wobei bemerkenswerterweise die Zahl zirkulierender 
Neutrophiler Granulozyten in entsprechenden Tieren mit der jeweiligen Läsionsgröße in der 
Aortenwurzel korrelierte. Die Ursache der Neutrophilie unter fettreicher Diät konnte 
maßgeblich durch eine veränderte Neutrophilen-Homöostase erklärt werden, welche im 
Einzelnen auf eine verstärkte Granulopoese, einer erhöhten Mobilisierung aus, sowie einer 
verminderten Rückführung alternder Neutrophiler Granulozyten in das Knochenmark 
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zurückzuführen ist. Es konnte weiterhin gezeigt werden, dass in der initialen Phase der 
Atherosklerose Neutrophile Granulozyten zur Entzündungsstelle rekrutiert werden. Dabei 
nutzten sie vor allem die Chemokinrezeptoren CCR1, CCR2, CCR5 und CXCR2, nicht jedoch 
CXCR4. Interessanterweise unterscheidet sich die aortale von der mikrovaskulären 
Rekrutierung. In entsprechenden Modellen waren ausschließlich CCR2 und CXCR2, nicht 
jedoch CCR1 und CCR5 auf den Neutrophilen Granulozyten erforderlich. Dies konnte 
teilweise durch wesentliche Unterschiede in der Deposition des CCR1 und CCR5-Liganden 
CCL5 zwischen beiden vaskulären Umgebungen erklärt werden. Als Quelle für CCL5 dienen 
maßgeblich Plättchen22, welche in neueren Untersuchungen immer öfter als therapeutisches 
Ziel avisiert werden33,42. Durch Depletion von Plättchen in Mäusen konnte eine signifikante 
Reduktion der Deposition von CCL5 in der Arteria carotis externa gemessen und in Folge 
dessen, auch eine Reduktion der Adhärenz von Neutrophilen verzeichnet werden. 
Im zweiten Teil dieser Arbeit wurden die beiden Untergruppen der Monozyten hinsichtlich 
ihrer Beteiligung in der Atherosklerose detailliert untersucht. Insbesondere konnte hier ein 
über CXCR2 und den Liganden CXCL1 funktionierender Mechanismus nachgewiesen werden, 
welcher zumindest zum Teil, die bereits schon von anderen Arbeitsgruppen berichtete 
erhöhte Zahl inflammatorischer Monozyten unter fettreicher Diät96 erklären könnte. 
Hinsichtlich der Rekrutierung dieser Zellen konnte eine klare Differenzierung der Funktionen 
verschiedener Chemokinrezeptoren erfolgen. Durch Korrelation der Zahl arterieller und 
zirkulierender Zellen konnten CCR1 und CCR5 als entscheidend für die Rekrutierung 
inflammatorischer Monozyten zur atherosklerotischen Läsion nachgewiesen werden. CCR2 
und CX3CR1 hingegen scheinen primär in der Homöostase der Monozyten relevant zu sein, 
nicht jedoch in der Rekrutierung, was durch adoptiven Zelltransfer weiter bestätigt wurde. 
Zusammenfassend lässt sich die bisher völlig unterschätzte Bedeutung der Neutrophilen 
Granulozyten in der Atherosklerose hervorheben. In Zusammenarbeit mit den 
inflammatorischen Monozyten scheinen sie besonders in der initialen Phase eine schädliche 
Partnerschaft einzugehen, da die Depletion Neutrophiler Granulozyten auch zu einer 
signifikanten Reduktion der Rekrutierung monozytärer Zellen führte. Die genauen 
Mechanismen, welche dieser Interaktion unterliegen sind soweit noch nicht eindeutig 
geklärt und es kann nur spekuliert werden. In anschließenden Studien soll dies noch weiter 
analysiert werden. 
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